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ABSTRACT   
Mitochondria are unique organelles, containing their own, maternally inherited genome. Human 
mitochondrial DNA (mtDNA) is small, circular and intronless, encoding 37 genes, precisely 13 proteins of 
the respiratory chain, 22 transfer RNAs (tRNAs) and 2 ribosomal RNAs. Each mitochondrion contains 
several mtDNA copies. Mitochondrial DNA deletions are pathogenic mutations that remove various 
portions of mtDNA genome, leading to shorter mtDNA molecules. In patients, there are two classes of 
mtDNA deletions: single, large-scale deletions that are present from the birth, whereas multiple 
deletions accumulate with age secondarily to mutations in nuclear genes involved in mtDNA 
maintenance. Every deleted mtDNA, coexists with other wild type mtDNAs, in an intracellular pool of 
mitochondrial genomes, determining the condition known as heteroplasmy. Pathogenic mtDNA 
mutations may become prevalent in certain cells; this process is defined as intracellular clonal expansion. 
This study investigates clonal expansion patterns of mtDNA deleted genomes, applying for the first time 
the droplet-digital polymerase chain reaction (ddPCR) approach on single muscle cells collected by laser-
capture microdissection from muscle biopsies of patients with different paradigms of mitochondrial 
disease with single and multiple mtDNA deletions accumulation. The results of this study indicate 
different patterns of accumulation of clonally expanded mtDNA deletions in patients with single and 
multiple deletions. It was found that single deletions patients have clonally expanded deletion in all single 
muscle cell populations, suggesting that the original deletion event occurred at early stage of embryonic 
development or even along the maternal germline transmission. Importantly, we distinguish localized 
clonal expansion of mtDNA deletions in patients with mutations in the OPA1 fusion gene. In conclusion, 
the ddPCR is a promising new technique for the investigation of clonal expansion by accurate quantifying 
of the mtDNA heteroplasmy levels. 
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1. MITOCHONDRIA 
1.1 THE BEGININGS 
 
The very first evidence of intracellular structures that probably represent mitochondria dates back to the 
1840s, only a few years after the discovery of the cell nucleus (Brown, R. 1833). 
In 1890, Altman first appreciated the recurrence of these structures that he named "bioblasts". His 
description was: "elementary organisms" living inside cells and carrying out vital functions. The name 
mitochondrion first appeared in 1898, used by Benda, and it emerges from the Greek "mitos" (thread) 
and "chondros" (granule), referring to the appearance of these structures during spermatogenesis 
(Ernster and Schatz, 1981). 
Today, more than a century from Altmann’s observations, we know that mitochondria are necessary 
organelles, powerhouses of eukaryotic cells. They produce ATP through the oxidative phosphorylation 
(OXPHOS). They are unique for containing their own maternally inherited circular genome (Giles, 1980). 
But, mitochondria have not always been cytoplasmic organelles, once upon a time they were free 
facultative aerobic bacteria (Ernster and Schatz, 1981).  
According to the endosymbiotic theory, first proposed by Lynn Margulis in the 1970s, mitochondria were 
originally bacteria, engulfed by ancestral cells but not digested. In return for security of host 
environment, mitochondria became the power supplier of the cell (Margulis, 1975).  
When exactly the symbiosis between eukaryotic cell and mitochondrion emerged? Probably between 
1.5 and 2 billion years ago (Lane, 2014; Martin, 2015). However, it was at the beginning of the eukaryotic 
life, which developed with multicellular organisms thanks to the energy produced through mitochondria. 
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1.2 MORPHOLOGY AND ACTIVITY 
From the bacterial ancestor mitochondria inherited, along with many other features, the double 
membrane system. The outer mitochondrial membrane (OMM) is the boundary to cytoplasm and also a 
place where mitochondria make contacts with their environment. In that sense, OMM is not just a simple 
barrier but has multiple roles that are vital for mitochondrial life and death. Maybe the most important 
is the interaction of OMM with endoplasmic reticulum (ER) at specific sites called mitochondria-
associated ER membranes (MAMs). Mitochondria require a regular and synchronized replenishment of 
membrane lipids to perform the physiological processes and maintain their membrane integrity. OMM 
and its ER connected sites are involved in many other important roles: calcium signalling, apoptosis, 
fission, and inflammation (Marchi, 2014). 
Voltage dependent anion channel (VDAC), a multispanning β-barrel protein often called mitochondrial 
porin, which provides high permeability to small molecules and ions, is placed at OMM. Overall, OMM 
operates like exchange hub for mitochondria.  
Between the two mitochondrial membranes there is the inter-membrane space (IMS), hosting a quite 
large pool of hydrophilic proteins (Marchi, 2014). 
The second membrane, the inner mitochondrial membrane (IMM) acts more privately, being 
impermeable to the majority of ions and smaller molecules. 
IMM is the site where energy conversion occurs and there are two structural regions to consider: the 
“boundary membrane” and the cristae, which are defined by narrow tubular sections named cristae 
junctions (Frey and Mannella, 2000).  
Structurally, a multitude of proteins are embedded in the IMM, most being constituents of the oxidative 
phosphorylation system (OXPHOS). The core of mitochondria is the matrix, a gel like structure containing 
enzymes of the tricarboxylic acid cycle and of β-oxidation. The oxidation-reduction reactions occurring 
mostly in association to the OXPHOS metabolism engage a large number of mitochondrial proteins. The 
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global mitochondrial proteome is currently estimated to contain up to 1500 proteins, and this number is 
constantly growing (Mao and Holt, 2009). 
As mentioned above, the IMM is highly invaginated to form structures called cristae (Palade, 1952). The 
tips of these invaginations are juxtaposed to the OMM, held together by the IMM integral protein OPA1. 
This organisation is important for the activation of apoptosis, because when the mitochondrial 
membrane potential declines or the intrinsic pathway of apoptosis is activated, the IMM proteases 
become activated and cleave OPA1. This results in the enlargement of the cristae junctions leading to 
release of luminal cytochrome c into the IMS (Burke, 2015; Frezza, 2006). However, not only apoptosis 
is dependent on cristae organization, but recent research highlights how respiratory efficiency and 
assembly of respiratory supercomplexes are tightly correlated with the cristae morphology (Cogliati, 
2013). 
 
1.3 LIFE CYCLE OF THE MITOCHONDRIA: MODERN NETWORKING ORGANELLS 
The idea of a discrete mitochondrion, isolated from the rest of the cell by the two membranes, seemed 
the right one for a long time. The endosymbiotic mitochondria, considered as discrete foreign entities, 
misled many to think mitochondria to stand alone within the cytoplasm of the cell. By means of 
tridimensional imaging techniques emerged the evidence that mitochondria are in fact very social 
organelles (Chan, 2012). Interconnected in highly dynamic networks, they move fast and can be in 
spotlight of cellular needs for energy. This network allows mitochondria to travel long distances, like 
along axons, and to be called up at active synapses. In conditions of oxidative stress, or nutrient 
starvation, the mitochondrial network is hyperfused, opposite to the G1/S cell phase transition, when 
mitochondria are elongated. So-called “mitochondria-shaping” proteins are in charge for regulation of 
organelles fusion and fission, two processes that are essential for managing the demanding 
mitochondrial network (Griparic and van der Bliek, 2001). Mitochondrial fusion is the process by which 
two mitochondria join to form a single mitochondrion, whereas fission is the process through which a 
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single mitochondrion divides into two mitochondria (Fig.1) (Chan, 2012). In the OMM, mitofusins (MFN) 
1 and 2, dynamin-related proteins that exhibit high homology, in tight cooperation with OPA1, 
orchestrate fusion (Santel and Fuller, 2001; Chen, 2003; Cipolat, 2004).  
The cytoplasmic dynamin-related protein 1 (Drp1) translocates to mitochondria upon 
dephosphorylation, regulating the process of mitochondrial fission (Cogliati, 2013; Smirnova, 2001). 
Recently, it has been shown that mitochondria can even be electrically coupled, without physical 
exchange of their matrix content, which normally happens during fusion, and this could be a way to 
simplify the energy transmission (Santo-Domingo, 2013). Further analysis of mitochondrial interactions 
points out that neighbouring mitochondria interact through specific inter-mitochondrial junction (IMJ) 
sites, where cristae membranes become structured into coordinated pairs across organelles (Picard, 
2015). 
This further level of interaction among mitochondria may provide a structural basis for events of 
electrochemical inter-mitochondrial communication, but further research in this exciting area is needed.  
 
Figure 1. Molecular mechanism of mitochondrial fission and fusion. The three molecular drivers of fission and 
fusion are shown as they associate with a normal mitochondrion. Fission (left) is initiated by recruitment of 
cytosolic dynamin-related protein 1 (Drp1) to the organelle, Drp1 oligomerization, and constriction of the parent 
into two daughters. Fusion (right) requires initial mitofusin 1 (Mfn1)/Mfn2-mediated OM tethering followed by 
fusion, and finally optic atrophy 1 (Opa1)–mediated IM fusion (from Dorn and Kitsis, 2015). 
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The maintenance of mitochondrial function is crucial for cellular homeostasis. Balance between fission 
and fusion is closely related to the homeostatic adjustment of mitochondrial mass to the metabolic 
needs of different tissues or sensing specific functional needs of cells (Mishra, 2014). Loss of this balance 
closely relates to regulation of apoptosis and cell death. Thus, maintenance of mitochondrial 
homeostasis is regulated by mitochondrial biogenesis, which provides newly synthesized organelles, as 
opposed to the autophagic elimination of damaged mitochondria, called mitophagy (Youle and Narendra 
2011). Impaired mitochondrial function caused by different mechanisms may result in a decrease in 
mitochondrial membrane potential. Depolarized mitochondria become fusion incompetent, they 
fragment through mitochondrial fission and can be selectively digested by lysosomes (Sarraf, 2013; Dorn 
and Kitsis, 2015). Mitophagy is part of the quality control system of cells to avoid the accumulation of 
damaged mitochondria that could eventually lead to apoptosis (Carelli, 2015). In the process of 
mitophagy, the PTEN-induced kinase 1 (PINK1) and Parkin, a cytosolic E3 ubiquitin ligase, play a crucial 
role (Narendra, 2010). Mitochondrial fusion is necessary for complementation of mutated mitochondrial 
DNA (mtDNA) (Chen, 2010). Fusion between damaged and healthy mitochondria has the potential to 
dilute out the damaged components, thus repairing the damaged organelle through functional 
complementation (Youle and Van der Bliek, 2012). However, there is always the opposite side of the 
coin, thus mitochondrial fusion may be considered as a mechanism leading to the pollution of healthy 
mitochondria, with damaged ones. Thus, it is important to bear in mind that fusion may also be the 
mechanism for dissemination of mtDNA mutations (Dorn II, 2015).  
1.4 OXPHOS 
Energy generation and consumption are prerequisite for life itself. This process is elegant, sophisticated 
and highly complex. In eukaryotes, respiration is a task carried out by the mitochondria.  
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The OXPHOS system is composed of five enzymatic complexes (CI-V) (Fig.2). It is built up by nearly 100 
polypeptides, of which only 13 are encoded by mtDNA, whereas the remaining are coded by the nuclear 
DNA (nDNA), and only subsequently imported within mitochondria (Carelli V., Chan D., 2014). 
Mitochondrial respiratory complexes (CI to IV) are responsible for the oxidation of the reducing 
equivalents, in the form of NADH or FADH2, originating from different metabolic pathways (glycolysis, 
fatty acid oxidation or the Krebs cycle). Oxidation of NADH and FADH2 is coupled with the pumping of 
protons into the IMS, and the resulting proton gradient is used by the ATPase (complex V) to generate 
utilizable energy in the form of ATP molecules. NADH reducing equivalents enter the mitochondrial 
electron transport chain (mtETC) through complex I, whereas FADH2 through complex II or other 
dehydrogenases. The electrons are then delivered to coenzyme (CoQ), and subsequently to complex III, 
cytochrome c, and complex IV, where the final acceptor oxygen is reduced to water (Acin-Perez and 
Enriquez, 2014). Altogether this processes is called respiration (Mitchell, 1961). Respiratory complexes 
are not present within the IMM as single entities but are organized in supercomplexes or respirasomes. 
Studies on isolated bovine heart mitochondria revealed a supercomplex consisting of one copy of 
complex I, one complex III dimer, and one or more complex IV monomer (Lapuente-Brun, 2013). This 
drives the path of electrons from NADH via the iron-sulfur clusters of complex I to ubiquinol, then to the 
prosthetic groups of complex III, and finally to molecular oxygen at complex IV. Genetic evidence 
provides strong support for the existence of respirasomes in vivo (Mileykovskaya, 2012; Koopman, 2013).  
The OXPHOS pathway is integrally coupled to the creation of reactive oxygen species (ROS). Under 
standard conditions, both cytosolic and mitochondrial ROS amounts are controlled by mitochondrial and 
cytosolic antioxidant systems and utilize a signalling function. Still, in case the ROS levels exceed the 
harmless limits, bypassing the antioxidant systems, DNA, proteins and lipid molecules are exposed to 
being damaged. If this exposure takes place over the years it leads to the slow decline of mitochondrial 
and overall cellular integrity and function (Koopman, 2013). 
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Figure 2. The mitochondrial electron transport chain and its association to ROS production. All respiratory 
complexes are coloured and specified with roman numbers (I-V). Transfer of electrons along the 
complexes (dotted arrows), proton (H+) transport (dashed arrows) in direction from the matrix to the 
IMS. Proton flow through ATP synthase (complex V) converts ADP to ATP. In normal conditions oxygen 
is the final electron acceptor from complex IV. However, damaged mitochondria may have electron leak 
from complexes I or III which produces toxic reactive oxygen species (ROS) (from Dorn G.W., 2015). 
 
2. MITOCHONDRIAL GENETICS 
 
2.1 STRUCTURE OF MITOCHONDRIAL DNA: THE MAGIC CIRCLE 
Whenever one thinks of mitochondria it must be kept in mind their bacterial origin, which helps to 
understand many distinguishing features of these organelles. Main characteristic, granting mitochondria 
to follow their own rules, is the existence of mtDNA. This little genome is maternally inherited and 
nowadays is just a 16.659 base pair long, circular, double stranded molecule that underwent various 
changes during evolution. Still, unorthodox, it remains as extra DNA in the eukaryotic cells (Carelli and 
Chan, 2014). 
The mtDNA contains 37 genes. Each mitochondrion contains several copies of this genome (Fig. 3) and 
this number varies between individuals and tissue types. The mtDNA codes for the 13 most important 
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OXPHOS polypeptides. These include seven from nearly 45 polypeptides composing the respiratory 
complex I (ND1-3, ND4L, ND4-6), one of the 11 polypeptides of complex III (cytochrome b, cytb), three 
of the 13 polypeptides of complex IV, and two of the 15 polypeptides of complex V (ATP6 and 8). Complex 
II (succinate dehydrogenase) is the only complex that has no polypeptides coded by mtDNA. Additionally, 
the mtDNA encodes the mitochondrial 16S and 18S rRNAs, and 22 tRNAs for mitochondrial protein 
synthesis (Wallace, 2013).  mtDNA has two strands, denoted as ‘heavy’ (H) and ‘light’ (L) strand, based 
upon their distinct base compositions, H strand is guanine rich while L strand is cytosine rich. Both strands 
of mtDNA are transcribed as long, polycistronic molecules, with transcription initiated from the heavy-
strand promoters (HSPs) and light-strand promoter (LSP), respectively (Wallace, 2007). The mechanism 
of mtDNA replication is still unresolved and has been lively debated in the past twenty years. Presently, 
three mechanisms for replication are proposed and will be discussed later on. Compactness of mtDNA is 
one more extraordinary characteristic, with no introns, two pairs of protein coding regions overlapping 
and only two non-coding regions. The first 1kb long non-coding region (NCR) of mtDNA is also a control 
region (CR), containing the origin for replication of H (OH) strand, as well as promoters for transcription 
of both strands HSP and LSP. A very enigmatic structure, residing in the control region, is the so-called D-
loop (Displacement loop) structure. In this region there is incorporated a third linear DNA strand referred 
as 7S DNA due to its sedimentation properties (Fig.3). The nomenclature of 7S DNA often induces 
confusion, since this is not one molecule but a group of molecules slightly different in size and with 5’ 
end that may start at various positions. The exact function of this region is still unknown; however it has 
been speculated that because it encompasses the origin of heavy strand replication and is positioned in 
the control region of mtDNA, is possibly involved in mtDNA maintenance, by control of dNTP pool and/or 
anchoring the mtDNA molecule (Nicholls and Minczuk, 2014). 
The second non-coding region is substantially smaller and contains the origin of L-strand replication (OL). 
It is located in a cluster of five tRNA genes approximately two thirds of the mtDNA length from the OH. 
The two origins divide the genome into roughly two-thirds and one-third sections, with the larger portion 
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denoted as the ‘major arc’, and the smaller portion called the ‘minor arc’ (Anderson et al., 1981; 
Fernandez-Silva et al., 2003).  
The circular molecule of mtDNA has a contour length of ∼5 μm and each mitochondrion, wide 
approximately ∼0.5 μm, contains numerous mtDNA circular molecues. Therefore, mtDNA has to be 
arranged to fit within a mitochondrion. This is accomplished by shaping the mtDNA in ellipsoidal 
structures termed nucleoids that present basic organizational units of mtDNA not wider than few 
hundred nanometers (Kukat, 2011; Kukat, 2015). 
Taking advantage of new stimulated emission depletion (STED) nanoscopy, electron microscopy and 
electron cryo-tomography (cryo-ET), it has been elucidated that most mammalian mitochondrial 
nucleoids contain a single mtDNA copy compacted by mitochondrial transcription factor A (TFAM) 
aggregation and cross- strand binding. TFAM is very abundant, present at approximately thousand copies 
per mtDNA molecule and besides being responsible for compacting mtDNA it has essential role in mtDNA 
replication as well as in transcription (Kukat, 2015). Expression of TFAM also governs the mtDNA copy 
number in cells, therefore this protein is irreplaceable for mtDNA maintenance. However, TFAM is not 
the only protein that affects the morphology and the organization of the nucleoids (Bogenhagen, 2012). 
Other proteins crucial for mtDNA maintenance are additional components of nucleoids: mitochondrial 
polymerase gamma (Polγ), mitochondrial single-stranded DNA binding protein, replicative helicase 
TWINKLE, mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M), mitochondrial 
transcription termination factor (mTERF), along with others (Bogenhagen, 2008; Kolesnikov, 2016). 
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Figure 3.    The human mitochondrial genome. The human mitochondrial genome consists of 16569 base 
pairs and contains a heavy (H-strand) and light-strand (L-strand). Complex I NADH dehydrogenase (ND) 
genes are presented in green; Complex III cytochrome b (Cytb) gene is presented in red; Complex IV 
cytochrome c oxidase (COX) genes are presented in light blue; Complex V ATP synthese (ATPase) genes 
are presented in grey. Transfer RNA genes are in black and ribosomal RNA genes (rRNA) are in yellow 
(from Wanrooij and Falkenberg, 2010). 
 
2.2 MITOCHONDRIAL REPLICATION, TRANSCRIPTION AND TRANSLATION 
All components needed for mtDNA transcription and replication are encoded in the nuclear genome, 
same as the mitochondrial translation machinery (Peralta S., 2012).  
 
2.2.1 MODELS FOR MITOCHONDRIAL DNA REPLICATION 
Strand displacement model 
Replication and turnover of mtDNA occurs independently from the cell cycle. The molecule of mtDNA is 
small and replicates within few hours. In the early 1980’s an extensive body of work has been done to 
define the rules of mtDNA replication (Bogenhagen, 1979; Nass, 1969; Tapper and Clayton, 1981). From 
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these studies the mtDNA replication model generated was denominated as strand-displacement model. 
This model implies that mtDNA replication starts with synthesis of the H strand near to the origin of 
heavy strand replication. Replication of heavy strand would than proceed and parental strand will be 
displaced. At about two thirds of genomic distance is the origin of light strand replication and when 
replication fork exposes this region the replication of the lagging strand may begin. This operational 
asynchrony of the two origins of mtDNA replication results in segregation of two different progeny 
circles, one of them requires single-strand gap filling before closure (Clayton, 1982). Strand- 
displacement model assumes that replication is unidirectional, without formation of Okazaki fragments, 
asynchronous and asymmetrical (McKinney and Oliveira, 2013) 
RITOLS (RNA Incorporated Through Out the Lagging Strand) model 
In the early 2000’s new replicative intermediates have been discovered with use of two-dimensional 
agarose gel electrophoresis (2DAGE). These new intermediates are essentially wide segments of RNA 
that are incorporated into the lagging strand hybridized to leading strand (Yang, 2002; Yasukawa, 2006). 
With use of antibodies specific to RNA-DNA hybrids it was shown that replicating mtDNA’s are duplexes, 
with RNA being present in long tracts, and these findings were confirmed with transmission electron 
microscopy (Pohjoismaki, 2010). 
The strand-coupled model 
This model was proposed from Holt et al. in the 2000. Essentially it assumes that mtDNA replication is 
more like to the one seen in bacteria, due to existence of theta like structures, double DNA replication 
intermediates found after artificially induced mtDNA depletion. By this model, replication starts from the 
broad zone and proceeds bidirectional (Bowmaker, 2003). It would be necessary, in this model, that 
Okazaki fragments are present and that two polymerases function simultaneously, and to date these are 
still not found. However, there are indications within the field that both RITOLS and strand-coupled 
model could represent alternative modes of mtDNA replication (Brown and Clayton, 2006). 
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2.2.2 MTDNA REPLICATION- REPLIOSOM 
Mitochondria contain enzymatic systems responsible for mtDNA replication, diverse from those in the 
nucleus, however all these proteins are encoded by nuclear genes (Figure 4).  To date, just three of these 
proteins have been identified operating at the mtDNA replication fork. Ahead of the fork, the replicative 
helicase Twinkle translocate on one DNA strand in 5’ to 3’ direction, unwinding double-stranded DNA 
into single-stranded DNA that now may serve as a template for DNA polymerase performing DNA 
synthesis. For the protection from nucleolysis, mtDNA bounds to the mitochondrial single-stranded DNA-
binding protein (mtSSB). Replication is primed by extension of processed RNA transcripts laid down by 
the mitochondrial RNA polymerase (Reyes, 2013). Part of replication enzymes, POLRMT, the catalytic 
subunit of mtDNA polymerase (POLγA), and the replicative mitochondrial helicase (TWINKLE) are similar 
to proteins encoded by the T-odd lineage of bacteriophages and not related to eubacteria (Shutt and 
Gray, 2006). 
 
 
Figure 4. The mtDNA replication machinery. The TWINKLE helicase (blue) moves in a 5' to 3' direction 
while unwinding dsDNA. The mtSSB protein (dark green) stabilizes the single stranded conformation and 
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stimulates the DNA synthesis by the POLγ (red (A) and gray (B)). POLRMT (light green) synthesizes the 
RNA primer (yellow line) needed for lagging strand DNA synthesis (from Wanrooij and Falkenberg, 2010). 
 
 
 
Mitochondrial DNA polymerase ϒ 
The only DNA polymerase found in mammalian mitochondria is the POLγ or POLG1 the enzyme 
promoting mtDNA replication and repair (Kaguni, 2004). 
The enzyme belongs to the family A group of DNA polymerases and human catalytic subunit POLγA has 
a molecular mass of 140 kDa. The catalytic subunit POLγA is associated with a smaller protein, the mtDNA 
polymerase γ accessory subunit (POLγB), which has molecular mass of 55 kDa (Gray and Wong, 1992). 
POLγA and POLγB form a heterotrimer (POLγAB2) in mammalian cells (Yakubovskaya, 2006); for sake of 
simplicity, later on the holoenzyme will be denoted simply as POLG. POLγB subunit significantly enhances 
the catalytic activity and the processivity of main subunit POLγA. To some extent this may be explained 
with enhanced binding of POLγA to mtDNA in the holoenzyme formation and also with increased 
nucleotide binding. Altogether this suggests that the accessory subunit has fundamental influence on the 
function of the catalytic subunit and allows for the most efficient binding of substrate (Falkenberg, 2007). 
POLγA subunit possess the enzyme’s 5’-3’ polymerase, 3’-5’ exonuclease and 5’ deoxyribose-5 phosphate 
lyase activities, and is probably the most studied polypeptide of the mtDNA replisome at the clinical, 
biochemical and structural levels (Stumpf and Copeland, 2011). Given that it is the only mtDNA 
polymerase, which functions in both mtDNA replication and repair, it is not surprising that research has 
been focused to disease-associated POLG mutations. Since the first POLG mutations were found to be 
associated with progressive external ophthalmoplegia (PEO) (Van Goethem, 2001), over 200 mutations 
in the POLG1 and POLG2 genes have been detected in association with various mitochondrial diseases 
(Akhmedov and Marin-Garcıa, 2015). 
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TWINKLE 
Mutations in the human Twinkle gene (C10orf2) were for the first time reported as a cause of autosomal 
dominant PEO, associated with multiple mtDNA deletions (Spelbrink, 2001). Later, biochemical studies 
showed the NTPase, 5’-3’ ssDNA translocase and dsDNA unwinding activities of the enzyme, identifying 
Twinkle as the replicative mtDNA helicase (Korhonen, 2004).  
 
Mitochondrial single-stranded DNA binding (mtSSB) 
This protein resembles Escherichia coli SSB and is the only protein of three replication-fork associated 
proteins that has no similarities with phage proteins (Tiranti, 1993). MtSSB binds to single-stranded DNA 
as a tetramer composed of four 16 kDa subunits (Yang, 1997). The protein stimulates synthesis of mtDNA 
by facilitating POLG primer recognition and enhancing POLG processivity (Genuario and Wong, 1993). 
MtSSB also stimulates the dsDNA unwinding activity of TWINKLE (Korhonen, 2003). 
Recent study of mtSSB protein showed this protein is highly abundant being present at more than two 
thousand units per mtDNA. It was demonstrated that mtSSB is actively recruited to nucleoids during 
mtDNA replication in vivo. MtSSB covers displaced single strands of replicative intermediates (Van Tuyle 
and Pavco, 1985). It was found that mtSSB is not evenly distributed over the genome, and that it 
associates exclusively with the H strand. Highest levels of mtSSB are downstream of the D-loop region, 
at the 3’ end of 7S DNA, and mtSSB levels gradually reduce towards OriL. A second, minor, peak of mtSSB 
take place just after OriL, but it weakens away going towards the D-loop region (Fuste, 2014). All these 
findings strongly favour strand displacement mode as primary mtDNA replication mechanism. 
 
2.2.3 TRANSCRIPTION 
In human cells, transcription initiation depends from promotor regions, and each strand has its own 
promoters: the light-strand promoter (LSP) and the two heavy-strand promoters (HSP). Transcription 
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from these promoters finally results in polycistronic precursor RNAs. These primary transcripts are 
processed to produce the individual mRNA, rRNA, and tRNA molecules (Montoya, 1981; Ojala, 1981; 
Clayton, 1991). 
Two heavy strand promoters HSP1 and HSP2 have been identified at the H strand (Micol, 1997). The 
HSP1 and HSP2 promoters are located very close, spaced by about 100 bp in the D-loop region and 
transcribed in the same direction (Martin, 2005). Transcription from the HSP1 promoter is prematurely 
terminated downstream of the 16S rRNA, transcribing only for the tRNAVal, tRNAPhe and the 2 rRNAs. 
Premature termination is result of a site-specific binding of the mitochondrial termination factor MTERF1 
(Roberti M, 2009). Transcription initiated from the HSP2 promoter produces a full-length polycistronic 
transcript covering the 2rRNAs (12S rRNA and 16S rRNA), 12mRNAs and 13 tRNAs.  All the protein-coding 
and rRNA genes are flanked by tRNA genes, which need to be excised in order to have mature mRNA and 
rRNA molecules (Falkenberg, 2007). 
Transcription from the LSP produces the RNA primers required for initiation of mtDNA replication at the 
origin of H-strand DNA replication (OH) (Clayton, 1991; Chang and Clayton, 1985). The molecular 
mechanism stopping the transcription and allowing the switch to primer formation is still not completely 
explained. However, very recent research showed that transcription and replication of mtDNA cannot go 
in parallel without interfering with each other.  It was proposed that in presence of human transcription 
elongation TEFM, mitochondrial RNA polymerase (mtRNAP) efficiently transcribes through termination 
sites of transcription (Agaronyan, 2015). 
As mentioned above, within the control region there are three conserved sequence blocks (CSBI- III) 
downstream of LSP (Walberg and Clayton, 1983). CSB II increases the stability of an RNA-DNA hybrid, and 
transitions from the RNA primer to the newly synthesized DNA have been mapped near CSBII 
(Falkenberg, 2007). Termination of transcription is still under investigation, since it is known just one 
exact termination site. This termination site is located at the end of the 16S rRNA gene, when 
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transcription starts from the HSP1 end (Christianson and Clayton, 1988). Transcription termination at 
this site is determined by the mitochondrial transcription termination factor (mTERF).   
The mitochondrial ribosome is shaped when mitochondrial ribosomes, 12SrRNA and 16S, form a complex 
with the mitochondrial ribosomal proteins (Pietromonaco, 1991). It is still unclear if 5S rRNA, which is 
imported within mitochondria, also assembles with mitochondrial ribosomes (Smirnov, 2011).   
 
2.2.4 TRANSLATION 
The components of mitochondrial translation are different from the cytosolic counterparts and, at the 
same time, there are also differences with the bacterial translation machinery. These differences concern 
not only the structure of the mitoribosome, which is more similar to the bacterial one, but in particular 
the number of associated proteins that is higher when compared to both the cytosolic and bacterial 
ribosomes. The role of most of these proteins is not assigned, but it is thought they may serve as a 
protection of rRNA from ROS insults (Lightowlers, 2014).   Translation of the mtDNA-encoded protein 
transcripts results in nascent polypeptides key for OXPHOS, while the other polypeptides of this system 
are translated in the cytosol. Not surprisingly the two translation systems are synchronized during 
mitochondrial biogenesis in yeast (Couvillion, 2016).  Mito-translation takes place through the following 
major steps: formation of initiation complex, elongation of the rising polypeptide chain, and termination, 
and recycling of the mitoribosome is considered as the final step of the process (Boczonadi and Horvath, 
2014).  The initiation complex consists from: 28S small subunit, mRNA, fMET-tRNA and IF2/3mt. When 
this complex is formed the mRNA enters into the IF3mt:28S subunit complex. The supposed role for 
IF3mt is to provide the right position of mRNA in binding the small subunit at the peptidyl (P) site of the 
mitoribosome. When the suitable start codon is matched, the formylmethionin -tRNA can bind to the 
first codon with the assistance of IF2mt. The assembly of the mitoribosome signals for release of 
initiation factors and the elongation proceeds on the 55S ribosome (Boczonadi and Horvath, 2014). 
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The mitochondrial elongation factor (EF-Tumt-GTP) and an amino-acylated tRNA occupy the A-site of the 
mitoribosome where truthful codon anticodon pairing takes place. If codon-anticodon pairing is correct 
than the elongation factor leaves the mitoribosome while the aminoacyl-tRNA moves to the P position 
where formation of peptide bond is catalysed leading to extension of the growing polypeptide chain. 
When the stop codon (UAA, UAG, AGA or AGG) comes across at the A-site, elongation stop is terminated 
(Boczonadi and Horvath, 2014). Stop codon is recognized, by the mitochondrial release factor (mtRF1a), 
which binds to the mitoribosome, inducing hydrolysis of the peptidyl-tRNA bond in the A-site, thus 
releasing the mature protein from the site (Richter, 2010). 
 
 2.3 INHERITANCE OF MITOCHONDRIAL DNA 
 
Among many peculiarities of mtDNA, inheritance is maybe the most intriguing. The mtDNA is inherited 
in a uniparental fashion, meaning that all the copies of mtDNA are passed to next generation solely from 
the mother (Giles, 1980). This implies that recombination of mitochondrial genetic material, if occurring, 
involves identical mtDNA molecules, raising the question why is there uniparental inheritance and how 
is this accomplished (Lane, 2012)? This question is still a matter of scientific debate, and a few recent 
studies may shed some light. First, the mtDNA sequence is highly variable even amongst individuals of 
the same mammalian specie and certain sequence polymorphisms can have influence even on acidity of 
the mitochondrial matrix (Gómez-Durán, 2010; Kazuno, 2006). As a consequence, mixing two distinct 
sequences, with different influences on certain physiological conditions, and with different variants in 
the same OXPHOS polypeptides may have harmful effects (Wallace, 2007). Indeed, a recent study 
showed that if two normal, but different mtDNA haplotypes are artificially mixed in the same mice model, 
an incompatibility manifests as the heteroplasmic state is unstable, resulting in a pathological phenotype 
with behavioural abnormalities (Sharpley, 2012). Second, different mtDNA haplotypes support equal 
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rates of ATP synthesis but differ in reactive oxygen-species (ROS) leak and mtDNA copy number. ROS 
leak seems to optimize ATP synthesis by stimulating mtDNA copy increase (Moreno-Loshuertos, 2006).  
Thus, for various possible reasons, the uniparental transmission of mtDNA is evolutionary conserved and 
favoured (Lane, 2011). But, how human paternal DNA gets eliminated? Two models are considered in 
the field: passive and active elimination (Carelli, 2015). First, the passive or “dilution” model reasons that 
paternal mtDNA, much inferior in copy number, is basically watered down away by the excess of oocyte 
mtDNA and consequently it is hardly detectable in the offspring (Sato and Sato, 2012). In accordance to 
this model, study done on mice showed paternal mtDNA elimination prior to fertilization, while 
infrequent not eliminated paternal mtDNA enters in the egg and could be found in newborn mice (Luo, 
2013). However, when this model was tested in humans, by examining heteroplasmy in buccal derived 
DNA from the children, confirmation for paternal mtDNA transmission was not found (Pyle, 2015). 
Second, the active elimination model predicts that paternal mtDNA is selectively eliminated, by 
ubiquitination or other still elusive mechanisms, in order to prevent its transmission to offspring. 
Mechanisms involved in this elimination are diverse, and may act at different pre- or post-fertilization 
levels (Carelli, 2015).  
 
2.4 MITOCHONDRIAL GENETICS AND HUMAN DISEASE 
 
Mitochondrial dysfunction underlies a large and diverse array of human diseases. The list of diseases in 
which mitochondrial dysfunction is recognized as a cause or a contributor to the pathogenic mechanism 
has been constantly growing in the past decade (Wallace and Chalkia, 2013). Many of the functions that 
mitochondria carry out in eukaryotic cell are key to survival, and have implications far beyond the energy 
supply. Independently from the energy production capacity, mitochondria affect a number of other 
cellular processes interfering with the expression of several thousands of genes linked to diverse cellular 
functions (Elstner and Turnbull, 2012; Latorre-Pellicer, 2016). The mtDNA has 100-1000 higher mutation 
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rate than nDNA and each cell variably contains 100-1000 copies of mtDNA. A subset of mtDNA molecules 
may carry pathogenic mutations, leading to the condition of intracellular heteroplasmy.  Nuclear genes 
implicated in mitochondrial functions are estimated to range from 1000 to 2000 (Pitchard, 2016). Thus, 
mitochondrial function may be of relevance for any complex disease. Individuals can accumulate 
different mtDNA mutations over time, impinging on the energetic capacity of the cell, and such clusters 
of mtDNA mutations are relevant for aging and cancer. Epidemiological surveys estimated that incidence 
of the most common pathogenic mtDNA mutations is one in 5000 (Schaefer, 2008). A second study of 
newborn cord bloods revealed that one in 200 infants harbour one of the 10 most common pathogenic 
mtDNA mutations (Chinnery, 2012). In general, mitochondrial diseases can be defined as a clinically 
heterogeneous group of disorders related with OXPHOS dysfunction. Mitochondrial disorders typically 
affect postmitotic and energy-demanding tissues, such as brain, heart or muscle, can appear sporadically 
or be maternally inherited  (Schon, 2012). There is no cure for mitochondrial disease and therapy is 
mostly limited to manage symptoms. Despite the fact that it is now well established that overall 
mitochondrial disorders cannot be considered rare, our understanding of the pathogenic mechanisms 
remains limited. 
 
3. MITOCHONDRIAL DNA DELETIONS 
The first pathogenic mtDNA mutations, deletions and point mutations, were discovered nearly three 
decades ago (Holt, 1988; Wallace, 1988). Both large-scale rearrangements (deletions or duplications) and 
point missense mutations of mtDNA have been linked to a vast array of clinical phenotypes. MtDNA 
deletions are pathogenic mutations that remove various portions of mitochondrial genome thus 
resulting in shorter molecules of mtDNA.  Circular deleted mtDNA is smaller than wild-type, due to the 
missing section of the genome, but it remains in a closed circular structure. The mtDNA deleted 
molecules are transcribed, but there is no evidence that the ”fusion” transcript crossing the deletion 
breakpoint is translated into a chimeric protein. On the other hand, mtDNA deletions remove a certain 
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number, depending on size and position of the deletion, of indispensable tRNA genes consequently 
disrupting the translation of key mtDNA-encoded respiratory chain polypeptides (Nakase, 1990). Thus, 
the deleterious effect of mtDNA deletions is out of any doubt. The phenotypic heterogeneity observed 
in patients carrying mtDNA deletions, imply however further elements to be considered, specifically the 
heteroplasmy and clonal expansion. In patients, we may distinguish two classes of mtDNA deletions: 
single and multiple deletions. These classes are based on inheritance pattern and the variety of deletions 
present. Furthermore, mtDNA sequence surrounding the deletion breakpoints may be used for 
classification of the mtDNA deletions. In fact, deletions may occur flanked by two direct repeats with 
identical sequences (class I deletions), flanked by imperfect repeats (class II deletions) and those that 
have no direct repeats (class III deletions). The deletions may vary in size from in the range from 2 kb to 
10 kb and may cover any mtDNA gene. Regardless of that, distribution of mtDNA deletions is not random; 
the mtDNA deletions are prevalent in the major arc of mtDNA, between two origins of the replication.  
Only 1.4% of all deleted regions, published and described in largest database of mtDNA deletions- 
Mitobreak (www.mitobreak.portugene.com), is located within the minor arc of mtDNA(Damas,2014). In 
single deletions the size of the deletion is associated with the severity of clinical phenotype, because 
larger the deletion is more mtDNA genes are removed, and consequently OXPHOS is more compromised 
(Grady, 2014). The location for the majority of deletions within the major arc explains the length 
constraint; the length of the major arc (11,230 nt) creates an upper limit for the size of the deletions.  
The central region of the major arc is often deleted, with the one ranging from positions 7,946 to 15,158 
being missed in more than half of cases and that ranging from positions 10,936 to 12,893, including tRNA-
His (TRNH) and tRNA-Ser (TRNS2) genes, being missed in 90% of cases (Damas, 2014).  A few studies 
identified a significant number of minor arc mtDNA deletions in sporadic inclusion body myositis patients 
(sIBM) and in elder people studied in ageing research (Rygiel, 2015; Bank, 2000). The two regions that 
cannot be deleted are the origin of heavy-strand replication and the light-strand promoter, as these 
regions are necessary for replication of both the deleted and wild-type mtDNA molecules (Moraes, 
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2003). The predominant deletion in the patient’s population is a 4977-bp deletion (“common deletion”), 
surrounding several mitochondrial genes encoding for structural proteins and tRNAs, and bordered with 
a long 13-bp direct repeat on both breakpoints (Schon, 1989). 
 
 
3.1 MITOCHONDRIAL DNA DELETIONS HETEROPLASMY AND CLONAL EXPANSION  
Every deleted mtDNA molecule exists mixed with wild type mtDNA molecules in an intracellular pool of 
mitochondrial genomes, making this pool non homogenous, and defined as heteroplasmic. When a new 
mtDNA mutation, in this case a deletion, arises it is just one mutant mtDNA molecule coexisting amongst 
thousands of non-mutant mtDNA molecules. Under these circumstances, the wild-type mtDNA easily 
compensates for the few mutant mtDNA molecules. Thus, low levels of mtDNA deletions can be easily 
tolerated, but once the mutant mtDNA molecules overcome a critical threshold level, a biochemical 
defect arises. This threshold level significantly varies between tissues and is distinct for different 
mutations. In the case of mtDNA deletions, the threshold level is proposed to be around 80%. In rapidly 
dividing cells such as hair or blood cells heteroplasmy of rearranged mtDNA is markedly shifted in favour 
of wild-type mtDNA (Moraes, 2003). A genetic drift during the germ-line bottleneck, characterized by a 
drastic drop in the number of mtDNA segregating units during oogenesis, can remarkably change the 
heteroplasmy levels between generations (Rebolledo-Jaramillo, 2014). 
Over time, the pathogenic mtDNA mutations (i.e. deletions) may become prevalent in certain cells, due 
to their clonal expansion, which may take place in both the germline and somatic cells. The mechanism 
beyond the clonal expansion is still poorly understood. Three major hypothesis deal with potential forces 
leading to clonal expansion of mtDNA deletions: replicative advantage of a smaller molecule, lover levels 
of ROS production and random genetic drift. 
The replicative advantage mechanism argues that deleted mtDNA molecules, due to being smaller size, 
are replicated faster than wild-type mtDNA, thus allowing for the mtDNA deletion to accumulate 
23 
 
(Wallace, 1992; Corral-Debrinski, 1992). This mechanism would provide a plausible explanation if two 
prerequisites are fulfilled. First, mtDNA replication needs to take significant amount of time in compared 
with time needed for mtDNA turnover, thus allowing for smaller molecules to accumulate. Second, this 
would imply that replicative advantage would favour larger deletions (Campbell, 2014).  Indeed, in 
agreement with this second prerequisite, two studies found that larger deletions accumulate in greater 
extent (Diaz, 2002; Fukui and Moraes, 2008, 2009), but this accumulation is observed only under relaxed 
copy number conditions and when no biochemical defect was observed, respectively. Another valuable 
study performed on patient tissues reported that there is no preferential accumulation of larger 
deletions over smaller deletions, under normal copy-number control. Given that mtDNA replication takes 
from one to two hours and time of mitochondrial half-life is estimated to be from one to three weeks, 
replication can hardly be rate limiting the turnover (Campbell, 2014). However, mtDNA point mutations 
are also accumulated by clonal expansion, and they cannot have any influence on the size of mtDNA 
molecule, thus replicative advantage of shorter molecules cannot be interpretation for the clonal 
expansion (Elson, 2001). 
Survival of the slowest hypothesis argues that because of decline in respiratory chain function, provoked 
by mtDNA damage, free radical production is also reduced. This way the compromised mitochondria 
manage to be spared from mytophagy and apoptosis as they are not considered as producers of toxic 
free radicals. Consequently the deleted mitochondria will predominate within a cell (De Grey, 1997). This 
hypothesis has not been supported by experimental evidence. 
The random genetic drift hypothesis implies there is no selective advantage for deleted molecules (Elson, 
2001). Random genetic drift model is established on validated rules of mtDNA replicative dynamics, 
which assume a relaxed mtDNA replication unrelated to the cell cycle, and is based on the mathematical 
models (Elson, 2001). On the other hand, evidences for significant levels of mtDNA deletions in the most 
of dopaminergic neurons of substantia nigra from older persons (Kraytsberg, 2006) contrasts with the 
predicted low levels of age-related COX-deficient cells, which should be less than 5% if only age driven. 
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Furthermore, this model does not explain the preferential accumulation of mtDNA deletions in certain 
tissues, under the assumption of a replicative turnover under relaxed replication and copy number 
control (Campbell, 2014). 
None of the proposed mechanisms fully explains the prevalent accumulation of mtDNA deletions in 
certain tissues and the consequent occurrence of a clinical phenotype.  
In muscle fibres, clonally expanded mtDNA genomes are found in specific, more or less restricted 
domains. These domains presumably represent areas with extended expansion process. Segmental 
nature of mtDNA clonal expansion is suggesting that mitochondrial fusion is restricted to some extent, 
and this is visible in elongated cells like muscle fibres. It seems likely and has been proposed that the 
dynamic processes of fusion and fission would affect the dimensions of segmental domains where 
deleted mtDNA expanded, becoming prevalent (Carelli and Chan, 2015). 
No matter the mechanism for arise of clonal expansion, it leads to local shifts in heteroplasmy rates, 
within cells or even within cell domains as in the case of skeletal muscle. Such heteroplasmy can vary 
between cells and tissues, making the phenotypic expression of a mitochondrial disorders difficult to 
predict. Thus, clonal expansion is the driving force leading to prevalent populations of deleted mtDNAs, 
ultimately causing the deleterious effect on mitochondrial OXPHOS and other metabolic pathways. 
Waiting to understand the mechanisms of clonal expansion, the distribution pattern of mtDNA 
heteroplasmy remains an unpredictable aspect of mitochondrial genetics (Wallace, 2013; Carelli, 2015). 
3.2 SINGLE MITOCHONDRIAL DNA DELETIONS 
Clinical features 
The first mtDNA mutations discovered in 1988, were in fact single mtDNA deletions and the Leber’s 
hereditary optic neuropathy point mutation, proving for the first time that mtDNA mutations cause 
human disease (Holt, 1988; Wallace, 1988). In patients with single mtDNA deletions, there is one 
prevalent deletion species exhibiting a wide tissue distribution. Single, large scale, deletions often cause 
a sporadic disease, which may be present from early childhood such as Pearson and Kearns-Sayre 
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syndromes or, later in life with chronic progressive external ophthalmoplegia (CPEO). As stated above, 
KSS, CPEO, and PS are sporadic disorders meaning that detectable mtDNA deletions are not found in 
other family members (mothers and maternal siblings)do not have detectable mtDNA deletions. 
Opposed to the single mtDNA deletions, large-scale mtDNA duplications are often maternally 
transmitted (Ballinger, 1992, 1994; Manfredi, 1997). Single deletions account for about a third of all 
patients with mtDNA-related disease (Mancuso M, 2015).  
Pearson's bone marrow-pancreas syndrome is a severe disorder, with high incidence of mortality. It 
involves the hematopoietic system, kidneys, exocrine pancreas and liver. The hallmark feature is 
sideroblastic anaemia, not typical for other mitochondrial diseases. The single type of mtDNA deletion is 
consistently found in all tissues, but in the blood it seems to be even more abundant and in neonatal 
period certain symptoms may differ from classical presentation (Manea, 2009). Pearson syndrome is 
often fatal in infancy. Individuals with Pearson syndrome who survive beyond infancy later on develop 
the neurological symptoms of Kearns-Sayre syndrome (Lee, 2007).  
Kearns-Sayre Syndrome (KSS) is a multisystem disorder affecting predominantly the central nervous 
system, skeletal muscle, and heart. Onset is usually in childhood, with ptosis, ophthalmoplegia, or both. 
Exercise intolerance and impaired night vision due to retinal dystrophy may be early symptoms (Auré, 
2007). A single mtDNA deletion is again found in all tissues. The disease usually progresses to death in 
young adulthood. 
Progressive external ophthalmoplegia (PEO) is a mitochondrial myopathy with drooping of the eyelids 
(ptosis), paralysis of the extraocular muscles (ophthalmoplegia), and variably severe proximal limb 
weakness. A few individuals with PEO have other manifestations of KSS and this situation is termed PEO 
plus. The disorder is quite benign, not affecting a normal life span. The single deletion occurrence is 
mostly restricted to skeletal muscle (Zeviani and Carelli, 2003). 
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3.3 INHERITANCE OF SINGLE MTDNA DELETIONS 
Single, large-scale mtDNA deletions are in most cases considered sporadic events occurring in the early 
stages of embryonic development of an individual (Zeviani and Carelli, 2003). However, there are studies 
showing that mtDNA deleted molecules may be present in the oocyte where mtDNA is sustained for long 
time up until fertilization. A few studies reported evidence of low levels (no more than 0.1%) mtDNA 
deletions in human oocytes (Chen, 1995; Brenner, 1998). If an oocyte containing a certain amount of 
mtDNA deletion is fertilized, the deleted molecules most probably will be lost by negative selection or 
purifying selection during the early stages of embryonic development. However, the genetic drift 
potentially occurring during the germ-line bottleneck may occasionally lead to prevalent mtDNA 
deletion, as result of the severe reduction in mtDNA copy number during oogenesis (Rebolledo-Jaramillo, 
2014). After fertilization, mtDNA variants are distributed among cells according to mitotic segregation, 
taking place upon fertilization, and it is assumed this process is leading to random distribution of 
mitochondria and mtDNAs during cell divisions (Poulton, 2010). Even if most times single mtDNA 
deletions are believed to be sporadic De Novo events, it cannot be excluded that they may in fact result 
from mtDNA bottleneck. The mtDNA germ-line bottleneck may provide a plausible explanation in the 
case of maternally inherited single mtDNA deletions, as the mother and maternal siblings of affected 
individual are healthy.  It is possible that a low-level mtDNA deletion segregates through the bottleneck 
and gets the opportunity of high expansion, eventually populating the primary oocyte (Krishnan, 2008) 
(Fig.5). In support of the bottleneck-derived germline transmission of deleted mtDNA there are a few 
cases of maternal inheritance in single mtDNA deletions that have been reported (Blakely, 2004; 
Shanske, 2002; Bernes, 1993). A good example is the case of a woman with sporadic CPEO who 
harboured a single large-scale mtDNA deletion, which was transmitted to her infant son, affected with 
PS. The single deletion of 5,355-bp in mtDNA, without flanking direct repeats, was the only abnormal 
species of mtDNA identified in both patients (Shanske, 2002). In another case reported, a woman, again 
with CPEO, and her son who also had a Pearson-like syndrome, both harboured the 4,977-bp “common” 
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mtDNA deletion. Although this case was similar to the previous one, the experimental analysis did not 
rule out the presence of duplicated mtDNA, which could have explained the transmission from mother 
to child (Bernes, 1993). In a third reported case, a woman and her daughter both had CPEO, but mother 
and daughter harboured different single mtDNA deletions (Ozawa, 1989).  
It is important to point out that these few cases with documented maternal inheritance of a single 
mtDNA deletion cannot be considered as definitive proof for the not sporadic nature of these mutations. 
In order to confirm maternal transmission, more cases should be thoroughly investigated. An important 
feature of mtDNA deletions is that they are usually not detectable in blood, except in the cases of Pearson 
syndrome, and muscle biopsy sampling of clinically unaffected mothers are ethically problematic. 
Therefore the development of highly sensitive approaches for detection of mtDNA deletions would be 
of outmost importance for understanding potential transmission of these deleterious mutations, and 
consequently would help in genetic counselling. 
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Figure 5. Illustration of a model for existence of sporadic mtDNA deletions in the oocyte. Formation of 
mtDNA deletion due to repair of oocyte mtDNA. The segregation of mtDNA deletion after fertilization 
and cell division.  If the segregation was at the level of primordial cell than extensive synthesis of mtDNA 
could lead to the prevalence of mtDNA deletion in the oocyte. If this oocyte is fertilized in future, a child 
born would be at risk of being born with high levels of an mtDNA deletion (from Kirshnan, 2008). 
 
 
3.4 MULTIPLE MITOCHONDRIAL DNA DELETIONS 
Shortly after the discovery of single, sporadic mtDNA deletions, the accumulation of multiple mtDNA-
deleted species was observed in families with recurrent cases of CPEO transmitted as an autosomal 
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dominant trait (Zeviani, 1989). Mendelian inheritance of mtDNA mutations appeared puzzling, since this 
genome is transmitted in a strictly maternal fashion. However, this observation was explained as the 
consequence of a dominant mutation in a nuclear gene leading to altered structural integrity of mtDNA 
(Zeviani, 1990). This hypothesis proved to be correct, as it led to the discovery that many genes 
responsible for familial CPEO were associated with multiple mtDNA deletions. Later one, it was 
determined that multiple mtDNA deletions may arise secondarily from mutations in nuclear genes 
involved in mtDNA maintenance. The list of genes involved in mtDNA maintenance, and thereby 
associated with multiple deletion formation, is constantly growing. Thus, the inheritance of these mtDNA 
deletions follows the classic Mendelian rules.  
These genes can be involved directly in mtDNA replication (POLG, POLG2, TWINKLE, RNASEH1, MGME1, 
and DNA2), but also in nucleotide pool balance (TYMP, SLC25A4, TK2, DGUOK, RRM2B, and MPV17) and, 
quite surprisingly, in mitochondrial dynamics (OPA1 and MFN2) (Sommerwille, 2014; Copeland, 2012). 
Also, mutations in genes difficult to categorize in aforementioned groups, are being correlated with 
multiple deletions like SPG7- paraplegin mutations and its partner protein AFG3L2, previously associated 
with dominant spinocerebellar ataxia type 28 disease (Gorman, 2015). Most recently, the CHCHD10 gene 
of unknown function was also found mutated in a few families with accumulation of mtDNA multiple 
deletions in muscle (Bannwarth, 2014). Thus, it is important to emphasize that these are not all mtDNA 
maintenance genes (Fig.6). Mutations in the nuclear encoded mitochondrial maintenance genes may 
cause two molecular phenotypes: mtDNA multiple deletions (“mtDNA multiple deletion disorders”) and 
reduction of mtDNA copy number (“mtDNA depletion syndromes”, MDS). The two molecular phenotypes 
may co-exist and are known collectively as mtDNA maintenance disorders (Kornblum, 2013). They can 
be either autosomal-recessive or -dominant mitochondrial disorders, in most cases with CPEO as the 
common clinical feature (Reyes, 2015). 
To complicate the scenario, mtDNA multiple deletions arise and accumulate also spontaneously as age-
dependent by-product of mtDNA replication in post-mitotic tissues. This somatic accumulation of mtDNA 
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multiple deletions characterizes certain subpopulations of neurons in neurodegenerative disorders, such 
as the dopaminergic neurons of substantia nigra in Parkinson disease (PD), as well as in elderly subjects  
(Carelli, 2015; Chan, 2015). Questions that still remain open are why in PD the accumulation of mtDNA 
deletions leads to detrimental consequences when the levels of deletion loads are similar in aged 
individuals? A very recent study reported that in elderly subjects the mtDNA copy number increased 
significantly with age and correlates with level of mtDNA deletions, whereas this compensatory affect 
fails in PD patients (Dolle, 2016).   
 
3.5 MITOCHONDRIAL DNA MAINTENANCE GENES AND MULTIPLE MTDNA DELETIONS 
Mutations in the DNA polymerase-γ (POLG) gene are a major cause of clinically heterogeneous 
mitochondrial diseases, associated with mtDNA depletion and multiple deletions. 
POLG is the only polymerase responsible for mtDNA replication, and knockout mouse for POLG show 
embryonic lethality (Hance, 2005). POLG-related disorders are currently defined by at least five major 
neurological phenotypes, that include: childhood myocerebrohepatopathy spectrum (MCHS), myoclonic 
epilepsy myopathy sensory ataxia (MEMSA), Alpers-Huttenlocher syndrome (AHS), the ataxia 
neuropathy spectrum (ANS), and chronic progressive external ophthalmoplegia (CPEO), some of them 
being fatal in early childhood (Wong, 2008). In individuals presenting with CPEO and multiple mtDNA 
deletions most likely the laboratory tests will find pathogenic mutations in POLG.  Psychiatric symptoms 
together with Parkinsonism are particularly prevalent in patients harbouring mutations of POLG. Other 
clinical manifestations include POLG-related encephalopathy and lactic acidosis and stroke-like episodes 
syndrome (MELAS)-like phenotype (Sommerwille, 2014; Hudson, 2006). In summary, both mtDNA 
depletion and accumulation of mtDNA deletions are important consequences of POLG mutations, but 
their reciprocal impact is variable among patients (Carelli, 2015). 
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C10orf2 (twinkle) encodes the mitochondrial protein twinkle, as mentioned above, this protein is DNA 
helicase that unwinds double stranded mtDNA in the 5’ to 3’ direction. This process is dependent on ATP 
and essential for mtDNA replication (Spelbrink, 2001). Two Twinkle mutations have been expressed in 
mice, dup352–364 and A359T, associated with CPEO in patients. The accumulation of mtDNA deletions 
was observed in the mouse muscle and brain tissues. The number of deleted molecules increased with 
age, along with the progressive respiratory chain dysfunction and myopathy (Tyynismaa, 2005). 
Dominant and recessive forms of PEO were reported in patients with C10orf2 mutations. Phenotypic 
spectrum seen in patients with Twinkle mutations is very diverse, including gait disturbance, exercise 
intolerance, diabetes mellitus, visual impairment, diplopia, hearing loss, ataxia, and seizures. Psychiatric 
symptoms are particularly common in these patients and may be any of the following, or combination of 
more symptoms, like: more or less severe depression and dementia, Alzheimer’s disease, avoidant 
personalities and other. Presence of mtDNA deletions is a hallmark of these mutations (Spelbrink, 2001; 
Van Hove, 2009; Sommerwille, 2014). 
Recently RNASEH1 was identified as another gene crucial for mtDNA maintenance. RNASEH1, encoding 
ribonuclease H1 (RNase H1), is an endonuclease that is present in both the nucleus and mitochondria 
and digests the RNA component of RNA-DNA. Patients first present with CPEO and exercise intolerance 
followed by muscle weakness, dysphagia, and spino-cerebellar signs with impaired gait coordination, 
dysmetria, and dysarthria (Reyes, 2015). Mouse knockout of RNASEH1 shows embryonic lethality due to 
failure to synthetize mtDNA (Carittelli, 2003). Deleterious RNASEH1 mutations slow down and stall 
mtDNA replication, causing both mtDNA depletion and deletions and ultimately leading to mitochondrial 
disease (Reyes, 2015). 
MGME1 (mitochondrial genome maintenance exonuclease 1), encodes a mitochondrial RecB-type 
exonuclease belonging to the PD-(D/E) XK nuclease superfamily. MGME1 cleaves single-stranded DNA 
and processes DNA flap substrates, also necessary for maintaining mitochondrial 7SDNA levels. By date 
only homozygous mutations in the gene are causing clinical phenotype characterized by ptosis in 
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childhood, followed by CPEO, diffuse skeletal muscle wasting and weakness, profound emaciation, and 
respiratory distress. Interestingly, mtDNA deletions from patients with MGME1 mutations were 
unusually large and detectable in DNA derived from blood (Kornblum, 2013).  
The molecular pathway responsible for the involvement of DNA2 in mtDNA is still under investigation. 
However, DNA2 encodes a helicase/nuclease family member that is most likely involved in mtDNA 
replication, as well as in the long-patch base-excision repair (LP-BER) pathway. Patients present with 
lower limb weakness, ophthalmoplegia, diplopia, myalgia and progressive myopathy. Multiple mtDNA 
deletions were reported in muscle (Ronchi, 2013). 
TYMP encodes thymidine phosphorylase which catalyses the conversion of thymidine to thymine and 
deoxyuridine   to   uracil   (El-Hattab, 2017).   Depletion   of   thymidine phosphorylase disturbs dNTP 
supply affecting mtDNA replication. Mutations of the TYMP cause mitochondrial neurogastrointestinal 
encephalopathy (MNGIE). This is a multisystem disorder and gastrointestinal dysmotility is the main 
symptom. Other common symptoms are CPEO, cachexia, muscle weakness, muscle atrophy and hearing 
loss. One of the hallmarks of MNGIE is somatic alteration of mtDNA, namely, depletion, multiple 
deletions, and site-specific point mutations (Valentino, 2007). 
SLC25A4 (ANT1) encodes ADP/ATP translocase1, as the name of this protein suggests it is necessary in 
the exchange of ATP generated within mitochondria and ADP present in the cytoplasm. Phenotype 
manifestation is associated to adCPEO and Senger's syndrome. Patients often have ptosis and 
neuromuscular symptoms, if present, are usually restricted to the facial muscles, mostly extra ocular. 
There were reports with psychiatric symptoms in patients (Sommerwille, 2014). 
TK2 encodes thymidine kinase 2, which phosphorylates thymidine, deoxycytidine, and deoxyuridine and 
is essential for dNTP generation for mtDNA replication. Thus, TK2 is an enzyme of the mitochondrial 
nucleotide salvage pathway and its loss-of-function mutations have shown to underlie the early-infantile 
myopathic form of mtDNA depletion syndrome (MDS). Heterozygous mutations lead to arCPEO, with 
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multiple deletions. Clinical presentation is with mild late-onset CPEO together with myopathy and central 
nervous system involvement (Tyynismaa, 2012). 
DGUOK encodes deoxyguanosine kinase, enzyme necessary for the first step of salvage of 
deoxyribonucleotides in the mitochondria. This function is essential for mtDNA maintenance.  
Heterozygous mutations with very late onset CPEO and ptosis were described to have multiple mtDNA 
deletions (Ronchi, 2012). Interestingly, the same mutations were found in in early onset mitochondrial 
disease patients with mtDNA depletion (Sommerwille, 2014). 
RRM2B encodes ribonucleoside-diphosphate reductase subunit M2 B (p53R2), protein that has essential 
role for dNTP supply for mtDNA replication, and consequently to its role it is involved in both mtDNA 
maintenance and repair.  Mutations in RRM2B, after POLG and TWINKLE, represent the third major number 
of adult-onset CPEO patients, and patients may have a broad spectrum of symptoms including milder 
CPEO, ptosis may occur but not necessary, exercise intolerance, muscle weakness, muscle atrophy, 
fatigue and hearing loss. Multiple mtDNA deletions are a common molecular finding in these patients 
(Sommerwille, 2014). 
MPV17 is a mitochondrial inner membrane protein, and its absence or dysfunction may cause OXPHOS 
failure and mtDNA depletion in affected individuals and in the Mpv17 knockout mice. Severe mtDNA 
depletion manifests as early childhood-onset failure to thrive, hypoglycemia, encephalopathy, and 
hepatopathy progressing to liver failure (Spinazzola, 2006). Homozygous mutation in MPV17 was found 
in Navajo Indian patients with infantile-, childhood-, or juvenile-onset neurohepatopathy (Spinazzola, 
2008). Heterozygous mutation was reported only in one patient, initially diagnosed with Charcot-Marie-
Tooth disease. Later in life patient developed other symptoms: progressive proximal limb weakness, 
exercise intolerance, diabetes mellitus, ptosis, ophthalmoparesis, hearing loss, gastrointestinal 
dysmotility and depression. MtDNA deletions are found only in one patient, thus MPV17 mutations 
manifest preferentially as mtDNA depletion disorders (Garone, 2012). 
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As discussed previously, OPA1 encodes the mitochondrial dynamin-like GTPase, inserted within the IMM 
and crucial for regulation of mitochondrial fusion and morphology. In 2008, both our and another group 
reported the occurrence of a multisystem disorder, named dominant optic atrophy plus (DOA-plus), 
characterized by severe optic atrophy, visual loss, sensorineural deafness and associated with 
accumulation of mtDNA multiple deletions in skeletal muscles (Amati- Bonneau, 2008; Hudson, 2008).  
Mutations in MFN2 gene are the most commonly identified cause of Charcot‐Marie‐Tooth type 2 (CMT2), 
a dominantly inherited disease characterized by degeneration of peripheral sensory and motor axons 
(Zuchner, 2004). Dominant MFN2 missense mutations may also lead to an optic atrophy plus phenotype.  
Importantly, both OPA1 and MF2 are involved in mitochondrial fusion machinery. Deletions of mtDNA 
were also found in patients with MFN2 mutations, providing further evidence that mitochondrial 
fusion/fission is necessary for mtDNA maintenance (Rouzier, 2012). 
CHCHD10 encodes a coiled-coil helix protein whose function is still unknown. It belongs to a family of 
mitochondrial proteins located in the IMS, some of which interact with OPA1 and are involved in cristae 
integrity and mitochondrial fusion (An, 2012). Families reported to have mutation in CHCHD10 had motor 
neuron disease, cognitive decline resembling frontotemporal dementia, non-CPEO myopathy, and 
accumulation of mtDNA multiple deletions in skeletal muscle (Bannwarth, 2014). 
SPG7 encodes paraplegin, which localises to the mitochondrial inner membrane. Typical presentation of 
symptoms is onset of either CPEO/ptosis and spastic ataxia, or a progressive ataxia disorder. 
AFG3L2 encodes AFG3-like protein 2, which forms a homo-oligomer, an m-AAA protease, with paraplegin 
in the mitochondrial inner membrane. Patients present with late-onset, slowly progressive ptosis and 
ophthalmoparesis with slurred speech and lower limb muscle weakness. So far, only two patients were 
reported with AFG3L2 mutations and CPEO with mtDNA multiple deletions (Gorman, 2015). 
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Figure 6. Mendelian disorders of mtDNA maintenance associated with multiple mtDNA deletions. A 
cartoon identifying the major genes which have been associated with disorders of mtDNA maintenance 
including multiple mtDNA deletion syndromes. Genes involved directly in mtDNA replication (italicised 
in green); involved in nucleotide pool balance (italicised in grey); involved in mitochondrial dynamics 
(italicised in black); with still not well defined function (italicised in light blue) and the sub-mitochondrial 
localisation of the proteins encoded by these genes (Trifunov, unpublished figure). 
 
3.6 MECHANISMS OF MTDNA DELETIONS FORMATION 
Many qualitative studies gathered a significant knowledge on the general characteristics of mtDNA-
deletions. Single and multiple mtDNA deletions are similar in size, may be flanked or not by repeat 
sequences and length of this repeats is similar between the two groups. These common features 
between single and multiple mtDNA deletions suggest that the same mechanism underlies their 
formation in different clinical settings (Krishnan, 2008).  
As discussed previously, the most reported mtDNA deletions occur in the major arc of mtDNA, between 
the two origins of mtDNA replication. This preferential location for mtDNA deletions is principal to the 
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hypothesis that mtDNA deletions rise by slipped-strand mispairing among direct homologous base-pairs 
during replication, if the replication is of strand displacement type. This is possible because this 
replication model implies presence of long single stranded DNA (Shoffner, 1989).  While replication is 
ongoing, the repeat of the H-strand, which is now single-stranded, may misanneal with the recently 
exposed L-strand repeat. This occurrence results with formation of a loop downstream of single-stranded 
parental H-strand that is later degraded with ligation of the free H-strands. After this event, replication 
is continued and results in formation of one wild type and one deleted mtDNA molecule (Fig. 7) 
(Pitceathly, 2012). 
 
Figure 7. Illustration of mitochondrial DNA deletion formation by slipped-strand model. (A) MtDNA 
molecule before replication with two direct homologous repeats (a/a1 and b/b1). The OH and OL are 
shown. (B)  Initiation of mtDNA replication starting at OH.  The daughter heavy strand (indicated with 
brown arrow) uses as a template the parental light strand simultaneously displacing the parent heavy 
stand. (C) Misannealing of direct bp repeat from the parent heavy strand (a) and the newly exposed 
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direct bp repeat on the parent light strand (b1), which results in formation of a loop downstream of 
heavy strand. The single-stranded loop is degraded until double-stranded DNA is reached, and this results 
with loss of the second parent heavy strand bp repeat (b). Ligation of the free ends of the parent heavy 
strand and continual replication of the daughter heavy strand. Replication of the daughter light strand 
starts when OL in the heavy strand is exposed; the parent heavy strand is used as template, in the 
opposite direction. (D) Result is the synthesis one deleted and one wild type mtDNA molecule (from 
Pitceathly, 2012). 
 
A different hypothesis suggests deletion formation during the repair of mtDNA at double-strand breaks 
(DSB), and not during the replication (Krishnan, 2008; Fukui and Moraes, 2009). This model proposes 
that mtDNA deletions are initiated by single-stranded regions of mtDNA generated through exonuclease 
activity at DSBs. This process takes place with nuclear single stranded DNA, allowing microhomolougus 
sequences to anneal. Eukaryotic cells have alert systems for DSB that alert for start of repair process 
(Pardo, 2009). In mtDNA, by the proposed model, DSB would provoke repair leading to subsequent 
ligation and finally degradation of the single strands (Fig.8). Altogether this may lead to rise of mtDNA 
deletion, as it was observed in mouse model that, due to induced restriction endonuclease with 
mitochondrial targeting, generates substantial amounts of mtDNA deletions (Fukui and Moraes, 2009). 
This model argues that if deletion formation would only occur during replication, higher levels of deleted 
molecules should be present in mitotic rather than post-mitotic cells (Krishnan, 2008). As discussed 
previously, in patients with different pathologies characterized by accumulation of mtDNA deletions 
occurs the opposite, since these are accumulated preferentially in post mitotic tissues.  
It is possible that the two models are not mutually exclusive. In different time points and dependant on 
the cell status, both mechanisms could occur and this issue still need to be fully elucidated.  
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Figure 8. Illustration of suggested model for generation of mtDNA deletions during the process of mtDNA 
repair. (a) Two direct repeats in mtDNA marked 3′ and 5′; (b) The DSB is generated. (c,d) The DSB is 
vulnerable to 3′→5′ exonuclease activity, further leading to the creation of single strands (d). (e) The 5′- 
and 3′-repeats may misanneal, which leads to degradation of the released single strands and ligation of 
the double strands. (f) Results is the creation of a deleted mtDNA, containing copies of both the 5′ and 
3′ repeats (from Krishnan, 2008). 
 
3.7 METHODS FOR QUANTITATIVE ANALYSIS OF HETEROPLASMY 
Quantification of deleted mtDNA is a difficult task, due to the fact that these molecules are always mixed 
with wild type mtDNA, thus requiring a highly sensitive approach. It becomes even more complex when 
quantification involves low abundance mtDNA deletions, because of technical limitations in sensitivity 
that usually require previous enrichment. Another important feature to be considered is the source of 
DNA to be used. Total DNA should be purified from a not fast replicative cell type, ideally from the 
muscle. If fast dividing cells, like hair or blood cells, are used as a source of mtDNA, the results may lead 
to wrong conclusions because heteroplasmy of mtDNA in these tissues is markedly shifted toward wild-
type mtDNA (Moraes, 2003). 
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 Southern blotting is the gold standard technique for the detection and quantification of most mtDNA 
rearrangements. This is not possible for single cells due to the quantity of DNA required and the limited 
sensitivity of the technique (He, 2002). The identification of deleted molecules is also possible using 
techniques such as long-range PCR, but this technique is not quantitative and has only the value of 
detection of a deletion (Reynier and Malthiery, 1995). This is the case also for the Southern blot, as for 
assessment of deletion heteroplasmy, densitometric analysis of the resulting band/s is used for 
heteroplasmy assessment. Another widely used technique for quantitative assessment of mtDNA 
deletions heteroplasmy is quantitative PCR. Assays for qPCR measuring mtDNA deletion level and mtDNA 
copy numbers (mtDNA CN) are abundant in the literature (He, 2002; Rygel, 2015; Philips, 2014). 
Quantitative PCR requires use of external standards, often in form of plasmid DNA, for quantification of 
mtDNA deletions. The size and breakpoint positions of many mtDNA deletions have been mapped in a 
large number of patients with single and multiple deletions (Damas, 2014). Generally, in quantitative 
PCR, two regions within mtDNA are detected at the same time: first region lays within the minor arc of 
mtDNA, where deletions hardly ever occur and a second region lays within the major arc where most 
mtDNA deletions span. By comparison of the target quantities the percentage of the deletion is 
calculated (He, 2002).  
Recently, a new and powerful technique, digital PCR (dPCR) was used for quantification of deleted 
mtDNA and was shown to be more precise, in comparison to more traditional qPCR (Belmonte, 2016). 
Droplet digital PCR is a variation of digital PCR offered by Bio-Rad (Hindson, 2011). Digital PCR can amplify 
a number of DNA copies, wherein the reaction simultaneously proceeds inside several thousands of 
nanoliter microspheres, thereby allowing higher data reliability.  The quantitative real-time PCR is 
commonly done in triplicate reactions, and the data are presented as arithmetic mean. However, in 
digital droplet PCR, numerous reactions happen simultaneously, which extensively decreases inaccuracy 
(Sofronova, 2016). An additional, prominent, benefit of ddPCR in heteroplasmy quantification is that it 
doesn’t require the usage of external standards, and also therefore results in lower error rates. 
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Partitioning of samples brings enhanced sensitivity and the final reaction is visualised using fluorescence 
rather than gel analysis (Belmonte, 2016; Manoj, 2016). New methods to increase the sensitivity of 
measuring mtDNA deletions are key to the diagnosis of primary mitochondrial disease. 
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Mitochondrial DNA deletions are pathogenic mutations removing various portions of this genome, thus 
resulting in shorter molecules. In patients, there are two classes of mtDNA deletions: single and multiple 
deletions (Holt, 1988; Zeviani, 1988). Single mtDNA deletions are in most cases sporadic and not 
transmitted, probably because they arise de novo somatically during early stages of embryogenesis. 
Multiple mtDNA deletions are generated secondarily to mutations in nuclear genes involved in mtDNA 
maintenance, thus they are inherited as Mendelian traits.  
The mtDNA deletions have been qualitatively investigated since they were first reported as causative 
human diseases. Quantitative investigation of mtDNA deletions has remained a demanding task, 
requiring highly sensitive technical approaches, due to the multicopy nature of mtDNA implying a 
heterogeneous population of deleted and wild-type molecules (Belmonte, 2016).  
The first aim of this study is to set more reliable quantification strategies for assessment of mtDNA 
deletions, which will be applied to determine heteroplasmy levels in muscle biopsy samples originating 
from different single and multiple deletion patients. To this end a new technique, the droplet digital PCR 
(ddPCR), is applied and compared with other, more traditional, methods such as Southern blot and 
quantitative real- time PCR.  
The second and final aim of this study is to investigate the clonal expansion as driving force leading 
toward prevalence of mtDNA deletions in certain cells. The mechanisms and dynamics of clonal 
expansion are still elusive and the distribution of mtDNA heteroplasmy remains an unpredictable aspect 
of mitochondrial genetics.  Clonal expansion acts at the single cell level, and for this reason droplet digital 
PCR (ddPCR) will be applied for the first time to quantitatively assess mtDNA deletions heteroplasmy and 
mitochondrial DNA copy number in single muscle fibres laser captured from patient’s muscle biopsies.  
Overall, dissecting the dynamics of clonal expansion may also lead to better understanding of germline 
transmission of mtDNA deletions, which is certainly necessary for preventing diseases due to these 
pathogenic mutations. 
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MATERIALS AND METHODS 
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1. Patients 
We selected 7 patients presenting with three different pathologies associated with mtDNA deletions: 2 
patients with dominant mutation in the OPA1 gene and a DOA “plus” syndrome, 2 patients with recessive 
mutations in the POLG gene and the SANDO syndrome (sensory ataxic neuropathy, dysphagia, 
ophthalmoplegia), and 3 sporadic patients with single mtDNA deletion and CPEO. This choice was done 
to represent three different categories of mitochondrial disorders: the patients with OPA1 mutations 
may accumulate mtDNA multiple deletions because of defective mitochondrial dynamics, the patients 
with POLG mutations present with pathological mtDNA maintenance due to defective mtDNA 
replication, and finally the patients with single mtDNA deletion are the paradigm of sporadic occurrence 
of mtDNA deletions. 
We also used 3 healthy, age-matched individuals as controls for this study. 
Patient 1:  
A 76-year-old man presented since he was young with the main symptoms of muscle weakness, gait 
unsteadiness, chronic and bilateral ptosis. Psychiatric symptoms included anxiety, panic attacks and 
depression. All these symptoms progressed and later in time he developed peripheral neuropathy, 
deafness, optic atrophy and Parkinsonism. At the time of biopsy he was 66 years old, and biopsy revealed 
cytochrome c oxidase (COX) negative fibres. The mtDNA analysis revealed the presence of multiple 
mtDNA deletions by long-range PCR. The patient belonged to a large family with dominant transmission 
of the same phenotype. Screening of candidate genes involved with multiple mtDNA deletions revealed 
heterozygous missense mutation in OPA1, affecting nucleotide c.1462G>A. This mutation affects 
conserved amino acid p.G488R in the GTPase domain of OPA1. This family has been previously reported 
(Carelli, 2015). 
Patient 2: 
 This is a 49 year old man who had poor vision since he was 4-year-old that progressed to complete 
blindness later in life. Since 9 years of age he also suffered a progressive hearing loss needing acoustic 
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prosthesis. At 30 years of age he developed gait difficulties with frequent falls due to peripheral 
neuropathy. At the time of muscle biopsy he was 42, and biopsy was positive for COX negative fibres. 
Electron microscopy of skeletal muscle showed mitochondria with morphologically abnormal cristae and 
accumulation of lipid droplets. Long-range PCR analysis of mtDNA revealed the presence of mtDNA 
multiple deletions. Screening of candidate genes was positive for the mutation c.1316 G4T affecting a 
conserved amino acid p.G439V in the GTPase domain of OPA1. The patient daughter developed the same 
phenotype and this case has been previously reported (Amati-Bonneau, 2008).  
Patient 3:  
This is a 63-year-old man with a multisistemic syndrome known with the acronym of SANDO. He suffered 
with ptosis and ophthalmoplegia by the age of 30; ten years later he started to develop a progressive 
skeletal muscle weakness and a sensitive polyneuropathy causing an ataxic gait. By the age of 50 he had 
dysarthria. His muscle biopsy showed a mitochondrial myopathy with Ragged Red Fibres and COX 
negative fibres. He carried two heterozygous mutations in the POLG1 gene (a missense mutation 
c.934T>C causing the amino acid change W312R and an insertion, 3629insA, causing a stop codon 
Y1210X). MtDNA multiple deletions were evident at long range PCR of muscle DNA. 
Patient 4: 
This 67-year-old woman suffered from ptosis and ophthalmoplegia from the age of 30 years. By the age 
of 56 years she clinically presented with ptosis, ophthalmoplegia, skeletal muscle weakness, peripheral 
polyneuropathy. A few years later she also developed dysphagia and a Parkinsonian syndrome with 
hypomimia, hypophonia, camptocormia and bradykinesia. Her muscle biopsy showed a mitochondrial 
myopathy with Ragged Red Fibres and COX negative fibres. She carried a homozygous missense mutation 
c.1943C>G in POLG1 gene leading to the amino acid change p.P648R. Multiple mtDNA deletions were 
evident with long range PCR. 
Patient 5: 
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This 50-year-old man started to develop a progressive bilateral ptosis and ophthalmoplegia by the age 
of 17 years. By the age of 45 years he suffered from diabetes mellitus, cardiomyopathy and skeletal 
muscle weakness. His muscle biopsy revealed numerous COX negative fibres. He carried a single mtDNA 
deletion of 4977 base pairs (nt. 8469-nt.13447). 
Patient 6:  
This 23-year-old girl suffered of monolateral ptosis by the age of 15 years without ophthalmoparesis. Her 
neurological examination was negative except for monolateral ptosis and electromyography didn’t show 
signs of myopathy and/or polyneuropathy. Audiometry was normal. She had lactic acidosis after aerobic 
effort and muscle biopsy showed a mitochondrial myopathy with COX negative fibres. She carried a single 
mtDNA deletion of 4977 base pairs (nt. 8469-nt.13447). 
Patient 7: This 55-year-old man developed by the age of 18 ophthalmoparesis and later, at 40 years, a 
bilateral progressive ptosis; he also presented with a mild peripheral polyneuropathy and neurosensorial 
hearing loss. His muscle biopsy showed a mitochondrial myopathy with COX negative fibres, without 
Ragged Red fibres. He carried a single mitochondrial DNA deletion of 5992 base pairs (breakpoint 
nt.9431-nt.15423). At the time of the biopsy he was 50 years old. 
Control 1: 37 year old female 
Control 2: 20 year old female 
Control 3: 41 year old female 
Control 4: 38 year old male 
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Table 1: Characteristics of samples used in this study 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Patient or 
control 
 Age at 
the 
time of 
biopsy 
 Age Sex Tissue 
sampled 
P1 OPA1  66 76 M Vastus L 
P2 OPA1  42 49 M Vastus L 
P3 POLG  53 63 M Vastus L 
P4 POLG  57 67 F Vastus L 
P5 SINGLE 
DELETION 
(Common) 
 49 50 M Vastus L 
P6 SINGLE 
DELETION 
(Common) 
 18 23 F Vastus L 
P7 SINGLE 
DELETION 
 50 55 M Vastus L 
C1 Control 1  37 NA F Vastus L 
C2 Control 2  20 NA F Vastus L 
C3 Control 3   41 NA F Vastus L 
C4 Control 4  38 NA M Blood 
DNA 
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2. Southern Blot 
Labelling of the probe 
As probe we used the whole mtDNA amplified by PCR in 11 products. The DIG DNA labelling and detection 
kit (Roche) was used to label the DNA with Digoxigenin-dUTP using random oligonucleotides as primers. 
In this method, the complementary DNA strand of denatured DNA is synthesized by Klenow polymerase 
using the 3′-OH end of the random oligonucleotides as primers. The labelling reaction was carried out 
according to manufacturer’s instructions. Briefly, 1ug of probe was diluted in 15ul of distilled water, 
boiled to denature for 10 minutes and cooled down in ice. To the denatured probe was added: 10x 
hexanucleotide mix, dNTP labeling mix and Klenow enzyme in appropriate volumes. Mixture was 
incubated at 37⁰C over-night and reaction was stopped the following morning by heating at 65⁰C. 
Hybridization mixture was stored at -20⁰C until hybridization. 
Restriction enzyme digestion and agarose gel electrophoresis 
Total genomic DNA was directly extracted from portions of frozen muscle biopsy tissues or from blood, 
with phenol-cloroform standard protocol. One microgram (ug) of DNA was digested with restriction 
enzyme BamHI (Thermo Fisher Scientific), following the manufacturer’s instruction. Restriction enzyme 
digestion was performed at 37⁰C and overnight. BamHI is restriction enzyme which cuts mtDNA just once 
at nucleotide position 14258, linearizing the mtDNA molecule. Digestions were separated on 0.8% 
agarose gel with Marker X (Rosche) by electrophoresis at 50V for 8h.  
DNA transfer to the membrane 
Following the digestion, filter paper and Mini Trans Blot filter paper (Biorad) were cut to the dimensions 
of gel as well as the positively charged nylon membrane (Boehringer Mannheim) and marked for 
recognising. Gel with digestions was placed in a dish with 50ml of 0.25M HCl for 15 min on shaker, for 
depurination and rinsed in distilled water.  Then soaked twice in 50ml of NaOH for 20min on shaker for 
denaturation of DNA. After denaturation, gel was rinsed in distilled water, and placed in a container with 
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50ml of neutralization buffer (1M Tris, pH 7.4; 1.5M NaCl) for 10min on shaker. In the meantime, plastic 
tray with two plastic hubs upside down and glass square was prepared. The glass was covered with filter 
paper, in a way that the ends of filter paper are touching plastic tray. In plastic tray and over the filter 
paper was poured 10X SSC buffer (prepared from stock solution 3M NaCl; 300mM Na3C6H5O7; pH 7). The 
gel was placed on filter paper upside down. On the upper side of gel was placed positively charged 
membrane in 2X SSC buffer. Membrane was covered with the membrane Mini Blot (BioRad) filter paper, 
and regular filter paper and paper towels until 10cm high. Second glass square was positioned on top 
together with 1kg of weight. The transfer from gel to membrane was overnight.   
DIG EASY HYB buffer (Roche) was preheated to hybridization temperature. The membrane was placed in 
a plastic tray and incubated with preheated buffer for 30 minutes at 42⁰C. The DIG-labelled DNA probe, 
prepared as described above, was denatured by boiling for 5min and rapidly cooling in ice. The denatured 
probe was added to pre-heated DIG Easy HYB buffer, and the membrane was incubated overnight 
incubation at 42⁰C. 
Washing the membrane, detection of luminescence and densitometry analysis 
Upon hybridization, membrane was washed in stringency buffers, two times for 30 minutes in each buffer 
(Buffer I- 0.02M Na2HPO4 with 5% SDS; Buffer II- 0.02M Na2HPO4 with 1% SDS; Buffer III- 0.02M Na2HPO4 
with 0. 5% SDS). Membranes were than incubated in blocking solution (Roche) diluted in maleic acid, to 
decrease the background in nonradioactive filter hybridization and the detection of nucleic acid hybrids. 
After blocking, membranes were incubated in Anti-Digoxigenin-AP Conjugate antibody (Roche) diluted 
1:5000 in blocking solution, and washed two times in Washing solution (Roche). After washing the 
membrane was immersed in CSPD ready to use (Roche) for 5 minutes in dark. CSPD is a chemiluminescent 
substrate for alkaline phosphatase that enables fast and sensitive detection of biomolecules by producing 
visible light. Light emission was recorded on luminescence imager system (Li-Core) and densitometry 
analysis was performed with Image Studio TM (Li-Core). 
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3. Preparation of recombinant plasmid for standard curve 
Total genomic DNA was extracted from blood of healthy controls. PCR primers were designed to amplify 
regions inside the ND1 and ND4 genes, a fragment of DNA in the NCR (noncoding region), and a fragment 
encompassing the common deletion breakpoints. PCR products were analysed on agarose gel, and DNA 
fragments were cut out and purified using QIAquick Gel Extraction kit (Quiagen). DNA was quantified by 
NanoDrop™ spectrophotometer. PCR products were cloned into vector TOPO® TA cloning (Thermo 
Scientific). Competent cells were grown in Luria–Bertani (LB) medium at 37⁰C containing, 50ug\ml of 
ampicillin and 25ug\ml of kanamycin, for the selection of recombinant clones. Positive clones where 
inoculated overnight in liquid Luria-Bertani medium at 37⁰C and plasmid DNA was isolated with 
GeneElute Plasmid Miniprep kit (Sigma-Aldrich). 
  
4. Quantitative real-time PCR 
PCR primers and fluorogenic probes (Integrated DNA Technologies) for all regions amplified are shown 
in Table 2. The absolute quantification method was achieved by standard curve generation. Serial 
dilutions of the recombinant plasmid were used for a standard curve for qPCR.  Region within minor arc, 
within ND1 gene was compared with region in the major arc the ND4 gene (Kirshnan, 2007, Philips, 2014). 
One microliter of DNA extracted from muscle biopsy homogenate was amplified separately with the 
ND1/ ND4 and D-loop/ND4 primer and probe combinations. To each sample 4.22 µl nanopure water and 
12.5 µl LightCycler® TaqMan® Master Mix were added. The concentration of all PCR primers was 300 nM 
and the fluorogenic probes 100 nM. PCR and fluorescence analysis was performed using the Roche 
LightCycler® 480 Instrument and detection system (Roche Molecular Biochemicals, Germany). 
Amplification conditions were: 2 min at 50°C, 10 min at 95°C then 40 cycles of 15 s at 95°C and 1 min at 
62°C (for probe/primer hybridisation and DNA synthesis). 
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5. Transversal and longitudinal muscle biopsy sectioning 
Quadriceps muscle biopsies, were taken under local anaesthetic from all patients as well as from healthy 
controls. All muscle biopsies (all from vastus lateralis) were frozen in liquid nitrogen-cooled isopentane 
and stored at −80◦C until processed. Adjacent 10-mm sections were cut using a cryostat microtome and 
fixed on PEN membrane glass slides (Thermofisher). In this study we used both transversal and 
longitudinal sections of the muscle biopsy. We were successful in obtaining the longitudinal sections 
from three muscle biopsies (patient 1, patient 4 and patient 5), it is very challenging to cut sections over 
long segments of an individual muscle fibre. This is in part because of the characteristics of tissue 
orientation, and also from a propensity of fresh muscle tissue to coil along the longitudinal axis 
6. Histochemical analysis and classification of individual muscle fibres 
To discriminate COX positive and COX negative muscle fibres, sequential COX/succinate dehydrogenase 
(SDH) histochemistry was performed on every section in the same incubation bath in parallel. COX 
activity was verified histochemically in a medium containing 4 mM 3, 3’- diaminobenzidine 
tetrahydrochloride (DAB) and 100 mM cytochrome c (Sigma) in 0.1 M phosphate buffer, pH 7.0 at 37 ⁰C. 
SDH activity was assayed by using 1.5 mM nitrobluetetrazolium, 130mM sodium succinate, 0.2 mM 
phenazine methosulfate, and 1.0 mM sodium azide in 0.1 M phosphate, pH 7.0 at 37⁰C. A 40-min 
incubation for COX activity was used, this allows detection of all histochemically demonstrable COX 
activity. The SDH reaction was incubated for 30 min, permitting the SDH in COX negative/SDH positive 
fibres to be demonstrated (Old, 1989). 
Upon COX/SDH staining, percentage of COX negative and intermediate fibres was determined (Table 3). 
According to COX/SDH staining fibres were classified as COX positive, COX negative, ragged red fibres 
RRB and intermediate. Intermediate fibres have grey colour due to brown/blue mixed reaction product 
in COX/SDH staining (Figure 12). 
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7. Laser Capture Microdissection  
The Leica laser capture microdissection (LCM) system (Leica Biosystems) was used, as described by the 
manufacturer’s instructions to isolate 12-mm thick COX negative, COX positive and intermediate regions 
of single fibres at both transversal and longitudinal sections. Prior to collection, each fibre was assigned 
a number and the total surface of the fibre was measured. This system uses UV laser and gravity 
collection. Presence of the single fibre in the collection tubes was always verified. Before microdissection, 
the tissue sections were subjected to an ethanol and dehydration series for 10–15 min at each step. 
8. Lysis of the single cells 
Muscle biopsies from seven patients and 3 healthy controls, prepared as described above, provided a 
source for individual laser microdissected muscle fibres. They were previously stained for COX/SDH 
activity. Individual COX negative (n= 70), COX positive (n=265) and intermediate fibres (n=98) were 
collected. Cells were lysed in 2.5ul of lysis buffer containing: 50mM Tris-HCl pH 8.5, 200ng/ml of 
Proteinase K (Invitrogen) and 1% Tween (Sigma). Cells were incubated for 16 hours at 55⁰C and then 10 
minutes at 95⁰C for denaturation of Proteinase K. After lysis, cells were digested for 1hour at 37⁰C with 
enzyme PvuII (Thermo Fisher Scientific) following the manufacturer’s instruction.  
9. Digital droplet PCR (ddPCR) assay 
The 20ul reactions consisted of 1X digital PCR supermix for probes (Bio-Rad Laboratories), 375nM of ND1 
probe, 900 nM of ND1 primers, 125nM of ND4 probe, 450nM ND4 primers and nuclease-free water. 
Reactions were transferred to 96well plates (Eppendorf) and droplet generation was carried out in an 
Automated Droplet Generator with DG32 cartridges (Bio-Rad Laboratories).Automated Droplet 
generator partitions samples into around 20,000 nanoliter-sized droplets, adding to each sample the 70 
μl of Droplet Generation Oil for Probes (Bio-Rad Laboratories). Droplets are automatically transferred to 
96-well plates and sealed ready for further amplification. PCR reactions were carried on C1000 Touch 
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thermal cycler (Bio-Rad Laboratories) using standard cycling conditions as follows:  95⁰C- 10 minutes, 40 
cycles of 94⁰C-30 s, 40 cycles of 60⁰ C-1min and 98⁰C- 10 minutes. 
Following PCR amplification of the nucleic acid target, droplets were analysed on QX200 Droplet Digital 
PCR (ddPCR™). Each droplet was analysed individually using a two-colour detection system (set to detect 
FAM and HEX); PCR-positive and PCR-negative droplets are counted to provide absolute quantification 
of target DNA in digital form using QuantaSoft™Pro software (Bio-Rad). Results are collected and visually 
examined in 1D and 2D plots (Fig 16). The levels of mtDNA wild type molecules is calculated by dividing 
the absolute number of MTND4 positive droplets with the absolute number of MTND1 positive droplets, 
and the percentage of mtDNA deletion is 1-wt molecules (He, 2002). The mtDNA copy number density 
was measured at the single fibre level and presents the total number of mtDNA molecules in a muscle 
fibre section, divided by the fibber’s cross-sectional area (Yu- Wai-Man, 2010). Each sample was assessed 
in triplicate. 
Table 2. Primers and probes used in qPCR and ddPCR experiments 
ND1 forward 5’CCCTAAAACCCGCCACATCT-3’ 
ND1 reverse 5’-GAGCGATGGTGAGAGCTAAGGT-3’ 
ND1 probe 5’-FAM/CCATCACCCTCTACATCACCGCCC/BHQ1-3’ 
ND4 forward 5’-CCATTCTCCTCCTATCCCTCAAC-3’ 
ND4 reverse 5’-CACAATCTGATGTTTTGGTTAAACTATATTT-3’ 
ND4 probe 5’-HEX/CCGACATCATTACCGGGTTTTCCTCTTG/BHQ2-3’ 
 
10. Single cell long range PCR 
Long range PCR was carried out using PrimeSTAR GXL DNA polymerase (TaKaRa, Clontech) on available 
DNA samples extracted from individual muscle fibres. Briefly, single muscle fibres were laser dissected, 
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lysed and digested as described earlier. Due to limited amounts of DNA quantification prior to PCR was 
not possible. Primer pairs were: forward 6222-6240 and reverse 16133-16153. Reaction was prepared 
as follows: 1× buffer, 0.2 uMdNTP mix, 0.4 uM forward and reverse primers, 0.625 unit polymerase and 
3ul DNA. Cycling conditions were: 94⁰C-1 min; 35 cycles of 94⁰C-10 s, 60⁰C-15 s and 68⁰C-10 min; 72⁰C-
10 min. Amplified PCR products were electrophoresed on 0.8% agarose gels. Smaller bands, suggesting 
the presence of mtDNA deletions were cut out of gels. DNA was extracted according to manufacturer’s 
protocol with QIAquick Gel Extraction Kit (Quiagen) and sequenced. 
11. Statistical analysis 
For the purpose of group evaluations, statistical investigation was done using GraphPad™ v.5.03 
statistical software (GraphPad Software). Group comparisons were considered to be statistically non-
significant (ns) if the calculated P-value was greater than 0.05, significant (*) with P = 0.01 to 0.05, very 
significant (**) with P = 0.001 to 0.01 and extremely significant (***) when the P-value was less than 
0.001. 
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RESULTS 
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1. Validation of Digital Droplet PCR (ddPCR) 
To quantitatively assess mtDNA deletions heteroplasmy in single cells, a ddPCR method was validated 
first on the total DNA extracted from homogenate of muscle biopsies. The results obtained were thus 
compared to the quantitative real- time PCR from the same samples and with Southern blot 
densitometric estimation of linearized mtDNA. Southern blot analysis and quantitative PCR methods are 
well-established methods for determining the amount of deleted mtDNA. For both quantitative real-time 
PCR and ddPCR, we analysed each sample in triplicate. For this validation we selected four patients 
(patients 2, 3, 4 and 6) from which the bioptic material was more abundant and we took care to include 
at least one patient per group. The mean values of deleted mtDNA load for patient 2 were 28.62% 
(SD=4.6) when assessed by qPCR, 37% by Southern blot densitometry and 9.06% (SD=0.75) by ddPCR. 
Similarly, in patients 3 and 4 the mean values with qPCR were respectively 50.58% (SD=2.4) and 73.10% 
(SD=2.3), 62% and 76% by Southern blot, and 44.39% (SD=3.1) and 70.50% (SD=2.6) by ddPCR. In patient 
6, harbouring a single mtDNA deletion, qPCR mean was 33.9% (SD=5), Southern blot was 74%, and ddPCR 
was 53% (SD=4). These results are summarized in Figure 9. Overall, by correlating the values obtained by 
each technique for each case there was a stronger correlation of the deletion load detected by ddPCR 
and Southern blotting (Fig.10A), as compared with qPCR (Fig.10B). Southern blot is considered a 
reference, being the only technique that does not imply a DNA amplification step, as it relies on the 
existing total DNA extracted from the sample. The highest discrepancies between Southern blot and 
ddPCR results were observed in patient 2 and patient 6. The most probable explanation for these 
differences can be in the probe used; in Southern blot, we probed the entire mtDNA while in ddPCR 
probes are located within MTND1 and MTND4 genes. Patient 2, where this difference was greater (37% 
by Southern blot densitometry and 9.06% of mtDNA deletions by ddPCR), suffers from multiple mtDNA 
deletions and it is possible that part of the deleted molecules encompass regions different than MTND1 
and MTND4 genes and/or are smaller and thus undetectable with our ddPCR assay. On the other hand, 
patient 6 with single deletion detectable by ddPCR, difference between Southern blot and ddPCR was 
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74% and 53%, respectively. In this case the possible explanation could be that Southern blot detects any 
mtDNA deletion potentially co-existing in the background of the prevalent single deletion.  
 
 
 
 
 
 
Figure 9. MtDNA deletions heteroplasmy levels. (A) Representative image for Southern blot. The 
positions of deleted and wild type (wt) mtDNA are indicated by blue arrows. (B) Comparison of 
heteroplasmy levels obtained with qPCR, ddPCR and Southern blot. Graph presenting mean values of 
qPCR measurements (red), ddPCR measurements (violet) and Southern blot densitometry (light yellow). 
Data for qPCR and ddPCR are means ± SEM of three independent experiments. 
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Figure 10. A- Correlation between mean values obtained for each patient with Southern Blot and ddPCR 
B- Correlation between mean values obtained for each patient with qPCR and ddPCR; r values present 
correlation coefficient; R2 values present coefficient of determination. 
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2. Proportion of COX negative and intermediate fibres throughout different patient groups 
 
The standard histoenzymatic diagnostic staining performed on muscle biopsies includes the COX 
(cytochrome c oxidase, complex IV) and SDH (succinate dehydrogenase, complex II) stanings, performed 
simultaneously. COX has 3 subunits encoded by mtDNA and classically becomes deficient when the 
mutational load of heteroplasmic mtDNA deleted molecules crosses a certain threshold. On the contrary, 
SDH is completely encoded by nDNA, thus the staining is not affected by deleted mtDNA or is even 
increased when compensatory mitochondrial biogenesis is activated. The overlapping of COX (yellow 
staining) and SDH (blue) results in brownish staining, with SDH/blue emerging when COX/yellow is 
reduced. 
Thus, the percentage of COX negative fibres for each biopsy used in this study (n=10) was visually 
determined. In healthy controls, as expected, COX negative fibres were absent. The lowest percentage, 
2.53% of COX negative fibres, was found in the biopsy from patient 1, with an OPA1 mutation, followed 
by 5% of COX negative fibres in patient 2 with a similar pathology. The highest values, 28.5% of COX 
negative fibres, was found in patient 5 with single “common” deletion, and 28.3% in patient 3 with 
mutations in POLG. We observed a modest correlation between age of the patients and the levels of COX 
negative fibres found in the biopsy (Fig.11). The percentage of intermediate fibres was lowest for the 
patients 1 and 2, 2% and 4.3% of intermediate fibres respectively. The highest load of intermediate fibres 
20.7%, was found in the biopsy from patient 3, whereas the second highest load, 18.5% of intermediate 
fibres, was found in patient 6, another patient with the single “common” deletion pathology. These 
results are summarized in Table 3. Representative images for biopsies are presented in figure 12. 
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Figure 11. Correlation between patients age at the time of biopsy with levels of COX negative fibres; r 
values present correlation coefficient; R2 values present coefficient of determination. 
 
     Table 3. Proportion of COX negative and intermediate samples 
Pathology Number of patient %COX negative %COX 
intermediate 
OPA1 Patient 1 2.53 2 
OPA1 Patient 2  5 4.3 
POLG Patient 3 28.3 20.7 
POLG Patient 4 12.5 16 
SINGLE 
DELETION 
Patient 5 28.5 16.5 
SINGLE 
DELETION 
Patient 6 3.94 18.5 
SINGLE 
DELETION 
Patient 7  10.8 20 
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Figure 12. Biopsy COX/SDH stain. A-Patient 1, COX negative fibre marked with number 1; B-Patient 2; C-
Patient 3, RRB fibre marked with number 2; D-Patient 4; E-Patient 5, COX intermediate fibre marked with 
3; F-Patient 6, COX positive fibre marked with 4; G-Patient 7; H-Control 1; I-Control 2;J-Control 3. 
 
3. Levels of mtDNA deletions in patients with OPA1 mutations 
We have assessed the deletion load by ddPCR in COX negative fibres (n=17), intermediate fibres (n=17) 
and COX positive fibres (n=27) from patients 1 and 2, both with mutations in OPA1 (Figure 13). Deletions 
were absent in two COX negative fibres from patient 1.  The mean value of deletion load in COX negative 
fibres was 78.54% (SD=30.83). In intermediate fibres deletion load had lower values with a mean value 
of 29.22% (SD=39). COX positive fibres from OPA1 group did not harbour mtDNA deletions, with a mean 
value of deletion load of 0.2473% (SD=0.75). This value is not significantly different from values found in 
COX positive fibres from controls (n=105) with a mean of 0.5234% (SD=1.3).  
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4. Levels of mtDNA deletions in patients with POLG mutations  
 
Patients 3 and 4 harboured mutations in POLG. We assessed deletion load in COX negative fibres (n=15) 
from these patients and found mean values of 81% (SD=13.3) (Figure 13). Among the COX negative fibres 
we also analysed the subcategory of ragged blue fibres (n=29). These fibres express the characteristic 
pattern of accumulation of abnormal mitochondria (massive proliferation and enlargement of 
mitochondria) that visually distinguishes them among the COX negative cells (Figure 12). The SDH 
reaction product is deep blue, with apparent dark blue fibre edges. These fibres usually express the 
highest levels of mtDNA deletions, as confirmed by our findings, being the mtDNA deletions mean value 
of 94.06% (Figure 14). Intermediate fibres (n=35) had deletion loads with mean values of 65.04% 
(SD=27.07). COX positive fibres from the POLG group (n=69) did not harbour mtDNA deletions, having a 
mean value for deletion load of 2.09% (SD=4) with no significant difference compared to controls.  
 
5. Levels of mtDNA deletions in patients with single deletions 
Patients 5, 6, and 7 had sporadic single deletion pathology. COX negative fibres (n=37) accumulate 
mtDNA deletions with a mean value of 93.08% (SD=5.38), while RRBs (n=23) have a mean value of 96.79% 
(SD=1.43). Intermediate cells bear mtDNA deletions with a mean value of 80.52% (SD=12.5). Surprisingly, 
more than 50%, 27 of 55 COX positive fibres, in the single deletion patient group harbour mtDNA 
deletions at variable percentages (Mean= 15.8% SD=25). 
 
6. Comparison of mtDNA deletion accumulation in all patient groups  
 
We observed that deletion levels in COX negative fibres from single deletion patients are significantly 
higher (P<0.05*) than in OPA1 and POLG patients, with a mean value of 93.08% of deletions respect to 
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78.5% and 81%. There were no significant differences between deletion levels of COX negative cells in 
OPA1 and POLG patients. Considering the RRB subcategory of COX negative fibres, that we found only in 
POLG and single deletion groups, there was a significant difference between the two groups (P<0.05*), 
with higher percentages of deletion loads in the single deletion patients (Fig.14).   
The intermediate fibres still have COX activity, but they are close to passing the threshold level for 
becoming COX negative.   It is known that threshold levels are variable between the different tissue 
types. Interestingly, we have observed that threshold levels are different at the single fibre level as well.   
Load of mtDNA deletions in single fibres varies in each phenotype group from a mean value of 29.2% in 
the OPA1 patients, 65.04% in POLG patients and 80.5% in single deletion patients. Again, the 
accumulation patterns of mtDNA deletions were significantly different (p < 0.0001***) when the three 
groups are compared.  
As COX positive fibres are considered to be healthy and have unchanged OXPHOS activity, these cells are 
not usually analysed.  However, there are few valuable studies that have sampled COX positive fibres, 
and described the presence of low levels of mtDNA deletions (Yu-Wai Man, 2010). Since all these studies 
were done with qPCR and used external standards in the form of plasmids, these low levels of mtDNA 
deletions were often assigned to qPCR error. We applied the ddPCR to a significant number of COX 
positive fibres collected from patients and healthy controls.    In total we examined 265 COX positive cells 
from healthy controls and patients.  We found that in COX positive cells from single deletion patients 
there was a significant accumulation of mtDNA deletions when compared with both POLG and OPA1 
patients and the healthy control group (P<0.0001***)(Fig. 13). Remarkably, more than 50% of all 
examined COX positive cells from single deletion patients, harboured the mtDNA deletions in various 
amounts. 
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Figure 13. Percentages of mtDNA deletions obtained with ddPCR in COX positive, COX negative and 
intermediate fibres across all patient groups and controls. Highest levels of mtDNA deletions in COX 
positive (brown dots), COX negative (blue dots) and intermediate fibres (grey dots) are observed in single 
deletion group. All measurements are in triplicate.  Mean values per each group of fibres are presented 
with black horizontal lines. 
 
Figure 14. Percentages of mtDNA deletions obtained with ddPCR in RRB fibres. RRB type of fibres was 
present only in single deletion and POLG group. RRB fibres from single deletion group express the highest 
level of mtDNA deletions. All measurements are in triplicate.  Mean values per each group of fibres are 
presented with black horizontal lines. 
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7. Deletion levels in longitudinal biopsy sections 
As discussed earlier, we successfully obtained longitudinal sections from three muscle biopsies (patient 
1, patient 4 and patient 5), representing one patient per group. This is due to difficulties in cutting single 
sections from end to end of the extensive segments of an individual muscle fibre, thus requiring a larger 
biopsy that was frozen and kept under optimal conditions. 
In our study, the longitudinal fibres analysis strengthened the results previously observed with cross-
sectioned fibres. Again, the single deletions group had the highest total levels of deletions in COX 
negative parts of fibres (mean=87.32%) as compared with POLG (mean=56.34%) and OPA1 
(mean=76.88%). Similar results were found in COX positive parts (Single deletion mean=42.78%, 
POLG=16.19% and OPA1=1.5%). The results are summarized in figure 15. 
 
Figure 15. Percentages of mtDNA deletions in longitudinal fibres obtained by ddPCR. Highest load of 
mtDNA deletions is in COX negative parts of fibre (blue dots) from single deletion group. All 
measurements are in triplicate.  Mean values per each group of fibres are presented with black horizontal 
lines. 
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In the case of POLG and OPA1 the areas of COX negativity were more localized, whereas in single deletion 
longitudinal fibres we noticed a wider dispersion of the COX negative domain (Fig.16). It was challenging 
to select fibres that contained both COX negative and COX positive zones and, at the same time, did not 
show blue staining across the entire fibre. To be sure that we collected truly COX positive zones in single 
deletion biopsy, we sampled the entire COX positive fibres that had no COX negative parts. We found a 
significant amount of mtDNA deletions in two entirely different COX positive longitudinal fibres (fibre 1: 
mean 29.96 %; fiber2: mean 60.38% mtDNA deletion).   
 
 
 
Figure 16. Representative images of longitudinal biopsy sectioning and 2D ddPCR plots. (A) Longitudinal 
biopsy section from patient 1 with OPA1 mutation. (B) Longitudinal biopsy section from patient 3 with 
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POLG mutation. (C) Longitudinal biopsy section from patient 5 with single deletion. (D) 2D ddPCR plot of 
COX negative part of fibre from patient 1. (E) 2D ddPCR plot of COX positive part of fibre from patient 1; 
blue dots represent ND1 positive droplets; green dots represent ND4 positive droplets; orange dots 
represent double positive droplets; grey dots represent empty droplets. 
 
 
8. MtDNA copy number levels show mtDNA proliferation in certain fibre types 
We compared total mtDNA copy per m2 between different fibre types and control fibres. MtDNA copy 
number was variable in the control group, ranging from 0.36 to 3.59 copies copies/ m2 with mean values 
1.71. This variability was also observed between our patients from all groups. This variability can be due 
to differences in metabolic activity, as it is well established that skeletal muscle is a highly adaptable 
tissue and that mtDNA density can be increased as a consequence of physical activity (Adhihetty, 2007). 
However, our results indicate that COX negative, RRB and intermediate fibres from the single deletion 
group showed significant increase in mtDNA density compared to healthy controls, similar to what we 
observed in RRB fibres from the POLG group. COX positive fibres from all groups as well as COX negative 
and intermediate fibres from POLG and OPA1 groups, did show increased values compared to controls, 
but not in the extent to achieve statistical significance  (Fig. 17). 
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Figure 17. MtDNA copy number density per mm2, assessed by ddPCR. All measurements are in triplicate.  
Mean values per each group are presented with black horizontal lines. The calculated P-value is denoted 
as very significant (**) with P = 0.001 to 0.01 and extremely significant (***) when the P-value is less 
than 0.001, when compared with the controls group. 
 
9. Single cell long range PCR confirms presence of mtDNA deletions   
To verify our findings in COX positive fibres from single deletion patients obtained with ddPCR, we used 
long- range PCR to amplify DNA extracted from longitudinal fibres. As discussed previously, long range 
PCR is not a quantitative method because of the preferential amplification of smaller mtDNA molecules. 
However, it was confirmatory to show the presence or absence of mtDNA deletions, especially 
considering the ddPCR results from COX positive cells in single deletion samples. Long range PCR analysis 
confirmed the presence of mtDNA deletions in single deletion COX positive cells (Fig. 18). 
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Figure 18. Single cell long range PCR. Representative images for detection of deleted mtDNA in single 
fibres from a single deletion P5 and DNA from muscle of control 1 by long range PCR. The positions of 
deleted and wild type (wt) mtDNA are indicated by blue arrows. 
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DISCUSSION 
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The single, large-scale mtDNA deletions were the first mutations of the mtDNA linked with human 
disease (Holt, 1988). However, almost 30 years upon their discovery many questions remain to be 
answered. Beside the mechanisms that lead to the formation and expansion of both multiple and single 
mtDNA deletions, the nature of the single mtDNA deletions inheritance remains “terra incognita” 
(DiMauro, 2013). Considering the few documented cases of maternal transmission and the large majority 
of cases described as sporadic, it remains difficult to conclude if these mtDNA mutations are early de 
novo somatic events occurring at any post-fertilization stage during embryogenesis, or they are inherited 
through the maternal germline, undergoing occasional expansion in single primary oocytes (Carelli and 
Chan, 2014). If they are de novo events, at which time point in embryonic development do they arise and 
what are the determining factors for their later clonal expansion? However, if they were transmitted 
through the maternal germline, than the bottleneck theory would explain why mothers and maternal 
relatives of affected children are healthy. Absence or very low loads of mtDNA deletions in fast dividing 
cells like blood cells, in conjunction with technical limitations and lack of highly sensitive approaches for 
their quantification, all contributed to the limited understanding we still have (Zeviani and Carelli, 2003). 
We designed our study to tackle the question of clonal expansion in single cells either of single or multiple 
deletions generated by different mechanisms. In particular besides patients with single deletions, we 
considered the two main causes of multiple deletions, i.e. defective mitochondrial dynamics as in the 
case of OPA1 mutations and impaired fusion, or defective mtDNA maintenance as in the case of POLG1 
mutations with increased replicative errors. We first validated the novel ddPCR technique applied to 
quantitatively assess mtDNA deletions and then adapted this approach to be used in the setting of single 
cell quantification. The ddPCR quantification turned to be reliable and accurate, due to the partitioning 
of the mtDNA molecules to thousands of nanoliter sized droplets, with the PCR reaction taking place in 
each of them, ideally starting from a single mtDNA molecule per droplet. We then combined ddPCR with 
laser capturing microdissection on single muscle cells, to explore the dynamics of clonal expansion at the 
72 
 
single cell level, and in different domains of the same muscle fibre as revealed by the histoenzymatic 
staining defining where OXPHOS was deficient and where not. Our results introduce novel findings on 
the clonal expansion of deleted mtDNA molecules in single cells, highlighting different patterns of mtDNA 
deletions accumulation according to the different pathomechanisms assumed: single deletions, 
defective fusion (OPA1 mutation) and defective mtDNA replication (POLG mutations). In particular,  we 
observed that in single deletions patients the deleted mtDNA is present at variable heteroplasmic loads 
across all fibre types (COX positive, COX negative, RRBs and intermediate), at amounts significantly 
higher than in patients with multiple deletions (OPA1 and POLG). This substantiates that the original 
deletion event occurred at a very early stage of embryonic development or even that is maternally 
transmitted via the germline. The distinctive feature of this study is that we have investigated the cell 
populations graded by histoenzymatic staining, both from patients and from control muscles. In this 
context we emphasize that the COX positive cells by definition do not suffer OXPHOS impairment. 
Consequently, the most remarkable result of this study is that in COX positive fibres from single deletion 
patients there is a substantial load of mtDNA deleted molecules, in some fibres reaching even high levels. 
This result was further confirmed when we analysed longitudinal fibres from the same patients, with 
high levels of mtDNA deletion even in the same COX positive fibres along its entire length. We also 
emphasize that this is the first study to investigate COX positive fibres from healthy controls. Earlier 
valuable studies on single muscle fibres investigated mtDNA deletions by quantitative PCR, in muscles 
from patients suffering single and multiple mtDNA deletions (He, 2002; Krishnan, 2007; Yu-Wai-Man, 
2010; Rygel, 2014). Coming to our results on patients with mtDNA multiple deletions we have shown 
that COX positive fibres from OPA1 patients did not accumulate mtDNA deletions being remarkably 
similar to controls. This is different from an earlier report on COX positive fibres from OPA1 patients, 
which observed that the majority of COX positive fibres harboured low deletion levels, less than 30% (Yu-
Wai-Man, 2010). The difference between the latter study and ours could be attributed to the different 
quantification methods, as with qPCR on blood from healthy controls we also observed the same low 
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values for mtDNA deletions, possibly artefacts. These artefacts may be explained with the necessity for 
external standards in quantitative PCR, resulting in false positive results. For validation of ddPCR we have 
tested a wide range of control DNA from blood and muscle (homogenate and single cells), and in all 
measurements the deletion levels were from 0-5%, indicating that ddPCR is a precise method for 
quantification of mtDNA deletions. 
As part of mitochondrial biogenesis and turnover, mitochondria can undergo fission and fusion events, 
enabling the regulation of mtDNA copy number (Carelli, 2015). Mitochondrial inner membrane fusion is 
orchestrated by OPA1 and pathogenic mutations in this gene are responsible for the majority of cases 
with autosomal dominant optic atrophy (DOA). Furthermore, OPA1 plays a role in apoptosis, 
maintenance of crista junctions and was shown to be necessary for the stability of respiratory chain 
complexes (Cogliati, 2013). Discovery of mtDNA deletions in patients with OPA1 mutations was an 
unexpected finding at the time, refocusing research toward the role of OPA1 in mtDNA stability; the role 
of OPA1 in nucleoid stabilization has been proposed. There is a substantial clinical heterogeneity in 
patients harbouring missense OPA1 mutations affecting the GTPase domain of the protein, reflecting the 
deleterious effects of impaired fusion not only for the optic nerve, but also for the brain, peripheral 
nerves and skeletal muscle (Burte, 2015; Hudson 2008, Yu Wai Man, 2010; Elachouri, 2011). 
Interestingly, our current results in the OPA1 group of patients showed localised clonal expansion of 
mtDNA multiple deletions. In this case, the fusion defect seems to favour the clonal expansion of pre-
existing deletions in single unfused mitochondria. On the other hand, these deletions seem to be 
insufficiently eliminated by mitophagy, when fusion is impaired. Our findings in the OPA1 group of 
patients (Figure 13), especially the results from our longitudinal fibres analysis (Figure 15), substantially 
support the recently identified existence of mitochondrial domains in the skeletal muscle (Mishra, 2015). 
These domains are regulated by OXPHOS capacity and the length of these domains is controlled by fusion 
proteins, clearly pointing to involvement of fusion in the dynamics of clonal expansion (Mishra, 2015). 
This study observed that, as response to lower OXPHOS capacity caused by genetically-driven 
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dysfunction or due to ageing, mitochondrial fusion rates become reduced and these mitochondrial 
domains displaying the OXPHOS deficiency become longer in length, thus spreading in distinct areas that 
end up as COX-negative domains (Figure 19). Our study confirms this model for the first time in humans, 
as highlighted by our patients with OPA1 mutation, where the fusion rates are lower, leading to COX-
negative segments where the mtDNA deleted molecules expand, in contrast with the adjacent COX-
positive domains where the amount of mtDNA deleted molecules is similar to controls. Thus, under this 
interpretation, in OPA1 patients the fusion defect increases the probability of clonally expand pre-
existing age-related mtDNA deletion, possibly in the absence of increased rate of mtDNA mutagenesis. 
 
Figure 19. Model connecting the OXPHOS activity and mitochondrial fusion in promoting health and 
limiting the spread of mtDNA defects in myofibers (Left).In healthy myofiber, oxidative activity promotes 
fusion of mitochondria across the sarcomere, leading to partial homogenization of the organelle 
population along the longitudinal axis. Z-lines are depicted in blue. (Right) Clonal expansion of the 
mutated mtDNA outcomes in decreased OXPHOS activity. This decrease leads to lower local fusion rates, 
promoting compartmentalization and restraining the spread of the mutant mtDNA genome throughout 
the fibre (from Mishra, 2015). 
 
POLG mutations cause a remarkable spectrum of clinical phenotypes. This is because POLG is the key 
enzyme involved in mtDNA replication and its mutations may lead to different molecular damage of 
mtDNA, including mtDNA base substitutions, deletions and depletion. The final result of these different 
mutations is a dysfunctional OXPHOS system. POLG-related disorders include both adult-onset 
mitochondrial diseases and childhood neurological disorders. (Horvath, 2006: Carelli and Chan, 2014). 
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In our study, patients with POLG mutation, due to the faulty mtDNA replication, which increases over 
time the pool of somatic deleted molecules, showed a tendency to clonally expand mtDNA deletions. 
This expansion is present at low levels also in the COX positive single muscle fibres, being at higher rate 
compared with control and OPA1 groups, but significantly less than observed within single deletion 
patients (Figure 13). Obviously, the compensatory mtDNA biogenesis becomes particularly activated in 
the COX-negative and RRB fibres of both single deletion patients and POLG cases with the SANDO 
recessive syndrome, as revealed by our assessment of mtDNA copy number (Figure 17). 
Altogether, our results lead to propose a model based on the hypothesis that efficiency of fusion is the 
key determining factor for regulating the dynamics and ultimately the final pattern of clonal expansion 
of deleted mtDNA. The difference between our model and the one proposed by Mishra in 2015, is that 
in the latter model the authors assumed that the OXPHOS defect reduces the levels of fusion that further 
lead to localized expansion of the mtDNA mutation. We may agree with the proposition that defective 
OXPHOS lowers the fusion rates. However, we do not know the exact threshold for defective OXPHOS 
after which the fusion activity becomes impaired. We propose that in patients that have mutations in 
the fusion OPA1 gene, fusion is disrupted and expansion of pre-existing age-related mtDNA deletions is 
promoted, explaining the overall modest accumulation of mtDNA multiple deletions, with essentially 
similar load of mtDNA deletions as controls in the COX-positive domains of individual muscle fibres. 
Furthermore, because of the fusion defect, fusion rates are lower and this promotes also a 
compartmentalization and limits the spread of the mutant mtDNA genome. We propose that the patients 
with POLG mutations may have less severe downregulation in fusion. This may be because the OXPHOS 
dysfunction again lowers the fusion as proposed earlier (Mishra, 2015). Differently, the single deletion 
patients, in our study, show the widest dispersion of the mtDNA mutation across the muscle fibre, 
opposite to the patients with OPA1 and POLG mutations. Consequently, it would be logical that fusion 
may become upregulated at some point in embryonic development. Under these, hypothetical, 
circumstances the upregulation of fusion would promote wider dispersion of the deleted mtDNA 
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molecules along the muscle fibers, overcoming the compartmentalization. Indeed, research of OPA1 
protein levels during zebrafish embryonic development pointed out that certain isoforms of OPA1 are 
highly abundant while others may be markedly reduced at specific stages of embryonic development. 
The same research identified, by gene expression analysis, a 50% up-regulation of genes involved in 
regulating mitochondrial biogenesis (including OPA1) at specific time point during embryonic 
development (Rahn, 2013).  Unfortunately, similar observations are not available for human embryos, as 
well as the information about possible fluctuations of fusion levels during oocyte maturation and in 
mature oocyte.    
 
 
Figure 20. Model: clonal expansion patterns of mutated mtDNA. (Right) Myofibre appearance in patients 
with mutation in OPA1 (fusion); due to mutations in fusion gene fusion is severely disrupted, this results 
in low fusion rates along longitudinal axis. Pre-existing mtDNA deletion remain localized. Due to presence 
of mtDNA deletion OXPHOS rates are lower. (Middle) Myofibre appearance in patients with mutations 
in POLG (disrupted replication and repair); Replication defect leads to significant accumulation of mtDNA 
deletions, lowering OXPHOS rates, fusion rates along longitudinal axis are less severe affected compared 
to when mutation in genes involved directly in fusion is present. Occasional fusion between wt mtDNA 
and deleted mtDNA along longitudinal axis may occur. (Left) Myofibre appearance in patients with single 
deletion; Clonal expansion in myofibre shows wide dispersion of mutated(deleted) mtDNA implying that 
fusion rates were high; promotion of fusion during certain stages of embryonic development may be the 
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reason why clonal expansion via fusion shows wide dispersion (Trifunov, unpublished figure, partially 
adapted from Mishra, 2015).  
 
 
Thus, bearing in mind that clonal expansion plays a crucial role in spreading the mtDNA deletions and 
acts at the single cell level, it is of outmost importance to elaborate on strategies to counteract this 
mechanism. This study identified droplet digital PCR as a reliable method for heteroplasmy 
determination within single muscle cells. However, more experiments are needed prior to introduce this 
quantification strategy as a diagnostic procedure. Analysis of longitudinal muscle fibres is an elegant way 
to visualize and sample segments with clonally expanded mtDNA deletion fitting with the cell domain 
displaying the COX defect, and we believe it could have wider application to study the patterns of mtDNA 
deletion accumulation in different tissues, at the single cell level.  
 
Finally, many questions regarding mtDNA deletions formation and subsequent clonal expansion wait to 
be further tackled. This study highlighted different patterns of mtDNA deletions accumulation by using 
for the first time the ddPCR on single muscle fibres. We are confident that new and more sensitive 
methods, like ddPCR, will ultimately provide answers in quantitative mitochondrial genetics, especially 
when it will be applied at the germline level, in primary oocytes, finally solving the origin of single mtDNA 
deletions. 
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